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ABSTRACT OF DISSERTATION

TOBACCO USE AND NICOTINE WITHDRAWAL AMONG
PATIENTS WITH MENTAL ILLNESS
People with mental illness (MI) are disproportionately affected by tobacco use
compared to the general population. In fact, it is estimated that people with MI consume
approximately 44% of cigarettes smoked in the United States. Moreover, the MI
population is at greater risk for the negative social, economic, and health consequences
associated with tobacco use and are reported to have 25-year shorter life expectancies
than the general population. The impact of tobacco use is further noticeable among
patients with MI who require psychiatric hospitalization. Quitting smoking in this
population has been linked to fewer discharges against medical advice, better quality of
life, and positive physical and psychological health outcomes. Thus, it is crucial to
identify and address factors such as nicotine withdrawal (NW) that may hinder successful
quit attempts among hospitalized patients with MIs. Given that many psychiatric facilities
have tobacco-free policies, NW is an important phenomenon to consider when delivering
tobacco treatment with this population.
The NW syndrome is a set of symptoms appearing after 24 hours of abrupt
cessation or reduction of tobacco after prolonged duration of use. NW has been
associated with impaired patient functioning, lower likelihood of quitting tobacco use,
and compromising care during psychiatric hospitalization. Approximately 65% of
patients hospitalized in a psychiatric facility with a tobacco-free policy experience NW
syndrome. Nonetheless, NW among hospitalized patients with MI is modestly examined
in the literature.
The purpose of this dissertation is to enhance our understanding of tobacco use
and NW among hospitalized patients with MI. Specific aims are to: 1) scrutinize and
synthesize the research literature examining NW among tobacco-using patients with MI
to outline correlates pertinent to this phenomenon, identify gaps in the literature, and
guide future research; 2) evaluate the psychometric properties of the Minnesota tobacco
withdrawal scale (MTWS) in capturing NW severity in the MI population during
psychiatric hospitalization; and 3) examine whether tobacco-using patients with certain

psychiatric diagnoses (psychotic disorders and mood or anxiety disorders) experience
varying NW severity, based on self-reported class of substance use (e.g., hallucinogens,
inhalants, alcohol) within the year prior to their psychiatric admission.
Aim 1 was achieved by conducting a systematic review of the literature using the
PsychINFO, MEDLINE, and CINAHL databases. The following correlates of NW
among people with MI in community and hospital settings were identified: psychiatric
diagnosis, sex, race, psychiatric symptom severity, alcohol and drug use, level of nicotine
dependence, nicotine replacement therapy and varenicline administration, confidence in
quitting, and levels of depression and anxiety. Aim 2 was achieved by conducting a
reliability and validity analysis of the MTWS in a sample of psychiatric inpatients. The
MTWS demonstrated adequate reliable and valid psychometric properties, and the
measure may be recommended for use in clinical practice to identify patients
experiencing NW. Aim 3 was achieved by performing a series of moderation analyses to
examine the nature of the relationships between psychiatric diagnoses and NW severity,
considering the patient’s substance use profile. Lower NW severity was observed among
patients with psychotic disorders who reported using hallucinogens; inhalants; opiates;
sedatives, hypnotics, and anxiolytics; stimulants; or poly-substances over the past year
than those who did not use these substances. Higher NW severity was documented
among patients with mood or anxiety disorders who reported using hallucinogens or
sedatives, hypnotics, and anxiolytics over the past year compared to those patients who
did not use these substances.
Considering the high prevalence of tobacco use among patients with MI
compared to the general population, a tobacco-free psychiatric hospitalization poses a
valuable opportunity to promote cessation. The results of this dissertation demonstrate a
need for protocols to better identify NW, based on specific patients’ characteristics, in
order to develop tailored interventions during psychiatric hospitalizations to limit barriers
to cessation and consequences of tobacco use in this population.
KEYWORDS: Nicotine Withdrawal, Tobacco Withdrawal, Mental Illness, Psychiatric
Hospitalization, Substance Use

Yazan Daher Al-Mrayat
(Name of Student)
05/08/2020
Date

TOBACCO USE AND NICOTINE WITHDRAWAL AMONG PATIENTS WITH
MENTAL ILLNESS

By
Yazan Daher Al-Mrayat

Ellen J. Hahn, PhD, RN, FAAN
Co-Director of Dissertation
Chizimuzo T.C. Okoli, PhD, MPH, MSN, RN
Co-Director of Dissertation
Debra K. Moser, PhD
Director of Graduate Studies
05/08/2020
Date

ACKNOWLEDGMENTS

I thank ALLAH for everything that led to this moment. Without his support and
help, I would not have made it this far, despite all the obstacles.
There are so many people I would like to thank who I worked with throughout all
of these past years. Thank you to my committee members: Dr. Ellen Hahn (committee
chair), Dr. Zim Okoli, Dr. Mary Rayens, Dr. Christina Studts, and Dr. Catherine Martin
(external examiner) for your expertise, guidance, and empowerment throughout this
journey. Dr. Okoli, I am speechless in thanking you for everything you have done for me.
I will be forever in debt to you.
I would like to thank my parents, brothers, and sisters, who have always
supported me during this journey and beyond. I would like to thank my beloved wife,
Ala’a, for being by my side and bearing with my continued absence over the past 4 years.
Thank you to my sons, Yanal, Rayan, and Wesam for their innocent love and support. I
hope you grow up to be more successful and better people.
Thank you to all the people I worked with, most notably, Heather Robertson, Dr.
Lovoria Williams, and Janet Otachi. Your support meant a lot to me. I also would like to
thank my dear uncle Dr. Ghazi Mrayat for his tremendous support, and my friends, Dr.
Majdi Rababa, Ahmad Abu Baker, Adnan Darwish, Mus’ab Shalash, Ibraheem Qasim,
and Ray Edwan. Finally, thank you to my dear Mutah University for supporting me
throughout these past years.

iii

TABLE OF CONTENTS

ACKNOWLEDGMENTS ................................................................................................. iii
TABLE OF CONTENTS .................................................................................................. iv
LIST OF TABLES ............................................................................................................ vii
LIST OF FIGURES ......................................................................................................... viii
CHAPTER 1. INTRODUCTION ....................................................................................... 1
1.1 Tobacco use and mental illness................................................................................. 1
1.2 Nicotine withdrawal defined ..................................................................................... 1
1.3 Nicotine withdrawal and MI ..................................................................................... 2
1.4 Substance use and NW.............................................................................................. 4
1.5 Conceptual model ..................................................................................................... 5
1.6 Purpose of dissertation .............................................................................................. 6
1.7 Summary of subsequent chapters.............................................................................. 6
CHAPTER 2. TOBACCO USE, NICOTINE WITHDRAWAL, AND MENTAL
ILLNESS: A SYSTEMATIC REVIEW ........................................................................... 11
2.1 Introduction ............................................................................................................. 11
2.2 Methods................................................................................................................... 13
2.3 Results ..................................................................................................................... 14
2.3.1 Study designs ................................................................................................... 15
2.3.2 Settings and sample sizes ................................................................................. 15
2.3.3 Participants’ characteristics and psychiatric diagnoses ................................... 16
2.3.4 Experimental design interventions ................................................................... 17
2.3.5 Measures used to assess NW ........................................................................... 17
2.3.6 Main findings of NW ....................................................................................... 18
2.4 Discussion ............................................................................................................... 20
2.4.1 Nationally-representative studies ..................................................................... 21
2.4.2 Psychiatric tobacco-free hospitalization .......................................................... 22
2.4.3 Tobacco users with psychotic, mood, or anxiety disorders ............................. 24
2.4.4 NW and tobacco users with alcohol or substance use disorders ...................... 27
2.5 Limitations .............................................................................................................. 28
2.6 Conclusion .............................................................................................................. 29
iv

CHAPTER 3. THE PSYCHOMETRIC PROPERTIES OF THE MINNESOTA
TOBACCO WITHDRAWAL SCALE AMONG PATIENTS WITH MENTAL
DISORDERS79.................................................................................................................. 47
3.1 Introduction ............................................................................................................. 47
3.2 Methods................................................................................................................... 50
3.2.1 Sample and setting ........................................................................................... 50
3.2.2 Design .............................................................................................................. 50
3.2.3 Measures .......................................................................................................... 51
3.2.4 Data analysis .................................................................................................... 53
3.2.5 Reliability testing ............................................................................................. 53
3.2.6 Validity testing ................................................................................................. 54
3.3 Results ..................................................................................................................... 55
3.3.1 Sample characteristics ...................................................................................... 55
3.3.2 Reliability testing ............................................................................................. 55
3.3.3 Validity testing ................................................................................................. 56
3.4 Discussion ............................................................................................................... 57
3.5 Conclusion .............................................................................................................. 60
CHAPTER 4. NICOTINE WITHDRAWAL AND SUBSTANCE USE AMONG
TOBACCO-USING PATIENTS WITH MENTAL ILLNESS ........................................ 65
4.1 Introduction ............................................................................................................. 65
4.2 Methods................................................................................................................... 68
4.2.1 Design .............................................................................................................. 68
4.2.2 Sample and setting ........................................................................................... 68
4.2.3 Measures .......................................................................................................... 69
4.2.4 Data analysis .................................................................................................... 71
4.3 Results ..................................................................................................................... 73
4.3.1 Sample characteristics ...................................................................................... 73
4.3.2 Psychotic disorders and NW ............................................................................ 74
4.3.3 Mood or anxiety disorders and NW ................................................................. 74
4.4 Discussion ............................................................................................................... 75
4.5 Conclusion .............................................................................................................. 80
CHAPTER 5. SUMMARY............................................................................................... 91
5.1 Background and Purpose ........................................................................................ 91
v

5.2 Summary of findings............................................................................................... 92
5.3 Contribution of dissertation .................................................................................... 94
5.4 Limitations .............................................................................................................. 95
5.5 Recommendations for future research .................................................................... 96
References ......................................................................................................................... 97
VITA ............................................................................................................................... 107

vi

LIST OF TABLES
Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco
Users with Mental Illness …….….……...…………………………………………..…30
Table 3.1 Differences in Sample Demographics and Clinical Variables by Cigarette
Equivalents per Day (N=255) ...…………………………………………….……….....61
Table 3.2 Item-total and Inter-item Correlations for the MTWS (N=255) ..…………...62
Table 3.3 Summary of Multivariate Regression Model (N=255) .………….…….…....63
Table 3.4 Loadings of the MTWS Items on the Identified Factor ..…………………....64
Table 4.1 Differences in Sample Characteristics by Primary Psychiatric Diagnosis
Categories at Discharge (N=255) ...………………………………………………….....82
Table 4.2 Parameters of Significant Interaction Terms for Separate Regression Models
Examining the Interaction of Psychotic Disorder Status and Different Substance Use
Classes on NW …………………………………………………………………………84
Table 4.3 Substance Use Moderators of the Relationship Between Psychotic Disorder
Status and NW ……………………………………………………………………..…..85
Table 4.4 Parameters of Significant Interaction Terms for Separate Regression Models
Examining the Interaction of Mood or Anxiety Disorder Status and Different Substance
Use Classes on NW ………………………………………………………………...….86
Table 4.5 Substance Use Moderators of the Relationship Between Mood or Anxiety
Disorder Status and NW ..…………………………………………………………..….87

vii

LIST OF FIGURES
Figure 1.1 Drug Motivational Processing at Low Levels of Negative Affect ..…………9
Figure 1.2 Drug Motivational Processing at High Levels of Negative Affect .....……..10
Figure 2.1 Diagram of Articles’ Selection Process ..……………………………….….46
Figure 4.1 Moderation analyses models for hypotheses 1 and 2. Substance use classes
include: alcohol; cannabis; hallucinogens; inhalants; stimulants; opiates – including pain
killers and heroin; sedatives, hypnotics, and anxiolytics; and poly-substance use ……88
Figure 4.2 Simple Slopes Analyses of Different Substance Use Classes for Patients with
Psychotic Disorders ….…………………………………………………………….…..89
Figure 4.3 Simple Slopes Analyses of Different Substance Use Classes for Patients with
Mood or Anxiety Disorders .....………………………………………………….…......90

viii

CHAPTER 1. INTRODUCTION
1.1 Tobacco use and mental illness
Compared to the general U.S. population, tobacco use among people with mental
illnesses (MI) is two- to three-fold more prevalent, especially for those with psychotic,
mood, anxiety, and substance use disorders.1 In fact, the prevalence of smoking increases
exponentially among those with a higher number of co-occurring MI diagnoses.1
Accordingly, an estimated 21-59% of people with MI currently use tobacco.2-7 This
considerable tobacco use prevalence rate in this population is best exemplified by the fact
that people with MI consume around 44% of all cigarettes smoked annually in the U.S.7
Consequently, people with MI have a shorter life-expectancy and are predisposed to a
higher incidence of negative smoking-related social and economic influences, diseases,
and deaths every year.1,8,9 On the other hand, quitting smoking in this population can
decrease the likelihood of being discharged against medical advice, lower anxiety and
depression, and enhance positive affect and quality of life.10,11 Therefore, it is crucial to
address factors that hinder tobacco cessation and promote quit attempts in this
population.
1.2 Nicotine withdrawal defined
Nicotine withdrawal (NW) syndrome is a well-known factor that decreases the
likelihood of quitting tobacco use. NW syndrome is a set of symptoms appearing within
24 hours of the abrupt cessation or reduction of a nicotine-containing product used on a
daily basis for a prolonged period of time.12 These symptoms typically include
irritability/frustration/anger, anxiety, difficulty in concentration, increased appetite,
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restlessness, depressed mood, and insomnia.12 Previously, the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) included the
decrease in heart rate as an eighth symptom of NW. However, this symptom was dropped
in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSMV).12,13 The DSM-V also specified that 4 or more of the NW symptoms need to be
present for a NW syndrome diagnosis.12 In addition to NW symptoms outlined by the
DSM-V, other clinical manifestations of NW include negative affect, working memory
deficits, increased dreaming, constipation, dizziness, coughing, craving, anhedonia, fear,
and mouth ulcers.14-16 Moreover, changes in physiologic parameters such as
electroencephalogram (EEG) power and heart rate have been observed within 12 hours of
smoking abstinence.17
1.3 Nicotine withdrawal and MI
It is estimated that up to 65% of patients with MI experience moderate-to-severe
NW symptomatology during a psychiatric tobacco-free hospitalization.18 NW among
people with MI is associated with fewer successful quit attempts, compromising
psychiatric care, clinically-significant distress, mood changes, and functional
impairment.11,12,19 Also, NW among patients with MI has been associated with female
gender, African American race, having greater psychiatric symptoms severity, lower
confidence in quitting, and having a diagnosis of an alcohol or other substance use
disorder.18,20
Using data from two large national surveys involving participants with and
without MI, Smith, Homish, Giovino, and Kozlowski (2014)19 found that MI accounted
for approximately 44% of NW diagnoses, with a greater likelihood of being diagnosed
2

with NW among people with MI, compared to those without. Specifically, as compared
to those without MI, the likelihood of NW was greater among people with psychotic
disorders, externalizing (past year alcohol use disorders and drug use disorders, and
lifetime antisocial personality disorder), internalizing disorders (past year mood and
anxiety disorder), and co-occurring internalizing disorders and externalizing disorders,
consecutively.19 Among community-dwelling individuals meeting criteria for an anxiety
disorder diagnosis, researchers found that these participants experienced greater
difficulties with NW during their quit attempt and had poor smoking cessation outcomes,
compared to their counterparts with no anxiety disorder diagnosis.21 Moreover, having a
lifetime diagnosis of major depressive disorder was associated with 2.5 times greater risk
for relapse due to NW, particularly for women with a history of alcohol use or
dependence.22 Similarly, higher likelihood of NW and associated relapse was found
among patients with alcohol and substance use disorder than patients with MI without
these disorders.22,23 These findings underscore the importance of addressing NW for
people with MI to enhance tobacco cessation and ultimately reduce tobacco use
prevalence.
Nicotine replacement therapy (NRT) (i.e., nicotine gum, patches, inhaler, and
lozenges) has been offered to psychiatric inpatients as a tobacco treatment measure used
to alleviate NW symptom severity during hospitalization.20,24 In these studies, NRT was
prescribed for patients with higher levels of nicotine dependence and prior use of NRT.
However, older and African American patients are less likely to be offered NRT during
their hospital stay.18 Interestingly, the timing of providing NRT may influence NW
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symptoms severity. The delayed receipt of NRT after admission was associated with a
more intense NW experience.20
Because tobacco-free psychiatric hospitalizations may intensify the experience of
NW among tobacco-using patients,12 a thorough understanding of this phenomenon
among psychiatric inpatients is necessary. The importance of exploring NW among
hospitalized psychiatric patients has become more emergent considering the increasing
trend of adopting tobacco-free policies across mental health institutions in the U.S.25-27 In
addition, as a strategy to ensure that providers address NW and tobacco treatment among
hospitalized psychiatric patients, the Centers for Medicare and Medicaid Services (CMS)
has implemented a reimbursement program for psychiatric facilities reporting specific
institutional tobacco treatment measures.28 Thus, psychiatric tobacco-free hospitalizations
introduce a valuable opportunity for health care professionals to reduce NW and assist
this population to engage in tobacco treatment.
1.4 Substance use and NW
Substance use among psychiatric patients is common, with around one-third of
patients with MI meeting criteria for at least one substance use disorder (SUD)
diagnosis.29-31 Specifically, in a Danish cohort, 46% of patients with personality
disorders, 32-37% of those with bipolar, schizophrenia, and schizoaffective disorders, 2528% of those with depression, anxiety, and other psychoses, 17% of patients with posttraumatic stress disorder, and 11% of those with obsessive-compulsive disorders were
reported to have co-occurring SUDs.32 Nonetheless, considering the relatively high
prevalence of SUD and NW among patients with MI, the nature of the relationship
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between the classes of substances used (e.g., opiates, cannabis, alcohol … etc.) and NW
during psychiatric hospitalizations has not been studied sufficiently.
1.5 Conceptual model
The Affective Processing Model of Negative Reinforcement33 was founded on the
roles that negative affect and motivation play in substance use withdrawal. Negative
affect is a manifestation of specific emotions, such as sadness, irritability, or anxiety.34,35
Regardless of the withdrawal syndrome symptom profile produced by different
substances, negative affect is a common feature in substance use withdrawal. Also,
negative affect is a marker of the aversiveness of the withdrawal syndrome, prompting
self-administration of the substance and relieving withdrawal symptoms rapidly after
drug administration. Because of the fluctuations in drug levels in a substance user’s body
over time, the user acquires a proceduralized drug motivational processing routine. In
particular, the user preconsciously detects interoceptive (internal) cues of negative affect
taking place whenever the drug level decreases in the body; which in turn produces
biased response options motivating the user to respond by using the drug to avoid the
resulting negative affect (see Figure 1.1). However, this proceduralized drug motivational
processing routine is only effective when negative affect levels are low.
On the other hand, experiencing a significant stressor and/or interrupting drug
use, in instances when the drug is unavailable, may produce high levels of negative
affect. These high levels of negative affect (which increase linearly with the withdrawal
duration) operate on the conscious level and influence information processing in a way
that biases the response options of the individual (i.e., using the drug to escape the
negative affect becomes the primary motivational concern) (see Figure 2.1). However,
5

cognitive control resources are believed to not operate at either high or low levels of
negative affect. The Affective Processing Model is employed in this dissertation to guide
our understanding of high levels of negative affect leading to the development of NW
symptoms during a psychiatric hospital stay due to the associated abrupt cessation of
tobacco use upon admission and the presence of a significant stressor (i.e., hospitalization
and/or exacerbation of MI condition).
1.6 Purpose of dissertation
The purposes of this dissertation are to: 1) synthesize and summarize the current
literature about NW correlates among tobacco users with MI; 2) critically evaluate the
validity and reliability of the Minnesota Tobacco Withdrawal Scale (MTWS) in detecting
NW severity among tobacco-using patients with MI during a psychiatric tobacco-free
hospital stay; and 3) examine the nature of the relationships between psychiatric
diagnoses and substance use classes on NW severity among psychiatric inpatients, in the
context of a tobacco-free psychiatric hospitalization. The three manuscripts presented in
this dissertation achieve these purposes.
1.7 Summary of subsequent chapters
Chapter two is a systematic review of the research literature on the factors
associated with NW among tobacco users with MI. Three electronic databases were
searched for research articles addressing NW among tobacco users with MI between
2008 and 2019. Research articles examining NW among tobacco users with no previous
substance use or MI were excluded. In addition, research articles examining NW using
neurobiological approaches were excluded. MI and its associated symptom severity, sex,
6

race, depression and anxiety factors, substance use, and nicotine use dependence and
treatment were associated with NW among tobacco users with MI. There were few
studies examining the progression of the severity of NW during outpatient or acute
tobacco-free psychiatric hospitalization settings. Moreover, there was a scarcity of
research investigating the association between the development of NW and use of alcohol
and other substances in tobacco users with MI.
Chapter three is a psychometric evaluation of the MTWS during psychiatric
hospitalization in a sample of 255 inpatients. Cronbach’s alpha and item analysis were
used to assess reliability, and hypothesis testing and exploratory factor analysis were used
to assess the instrument’s validity. The analysis revealed adequately reliable parameters
in terms of Cronbach’s alpha, item-item correlation coefficients, and item-total
correlations. Factor analysis revealed a unidimensional scale and hypothesis testing
confirmed the construct validity of the scale. However, the generalizability of findings
was limited primarily by the convenience nature of participant sampling, i.e., data from
participants represented only 24% of the total tobacco-using patients admitted to the
psychiatric facility over a 12-month period.
Chapter four is an observational study using moderation analysis to examine the
relationship between selected psychiatric diagnoses (i.e., psychotic disorder vs. not; mood
or anxiety disorder vs. not) and NW severity during a psychiatric hospital stay, when
certain classes of substances (e.g., sedatives, hypnotics, and anxiolytics) were used preadmission. Lower NW severity was observed among those with psychotic disorders
coupled with the reported use of inhalants; opiates; hallucinogens; sedatives, hypnotics,
and anxiolytics; stimulants; or poly-substance. Higher NW severity was found among
7

patients with mood or anxiety disorders who reported use of hallucinogens or sedatives,
hypnotics, and anxiolytics. Tobacco users with different MI diagnoses and substance use
profiles may experience different NW severity during tobacco-free hospitalizations.
Chapter five is a synthesis and summary of the results found in this scholarly
work. Implications of the findings for advancing the science of NW with tobacco users
with MI are discussed. Recommendations for practice and policy are also offered for
consideration.
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Figure 1.1 Drug Motivational Processing at Low Levels of Negative Affect

9
Adopted from Baker, T. B., Piper, M. E., McCarthy, D. E., Majeskie, M. R., & Fiore, M. C. (2004). Addiction motivation
reformulated: an affective processing model of negative reinforcement. Psychological review, 111(1), 33.

Figure 1.2 Drug Motivational Processing at High Levels of Negative Affect

10
Adopted from Baker, T. B., Piper, M. E., McCarthy, D. E., Majeskie, M. R., & Fiore, M. C. (2004). Addiction motivation
reformulated: an affective processing model of negative reinforcement. Psychological review, 111(1), 33.

CHAPTER 2. TOBACCO USE, NICOTINE WITHDRAWAL, AND MENTAL
ILLNESS: A SYSTEMATIC REVIEW
2.1 Introduction
Significant accomplishments have been made in reducing the prevalence of the
tobacco use epidemic in the U.S. over the past few decades. The Centers for Disease
Control and Prevention (CDC) stated that the percentage of currently-smoking adults in
the U.S. has declined from 20.9% in 2005 to 13.7% in 2018.37,38 However, the percentage
of current smokers with serious psychological distress in 2018 was 31.6%.38 Further, the
prevalence of smoking among people with serious psychological distress is greater now
than among the general public 30 years ago.39 This discernible gap in the smoking rates
between these two groups may be attributed to the relatively high relapse rate among
people with serious psychological distress who attempt to quit.40 Therefore, it is crucial to
assess factors hindering tobacco treatment services which contribute to high relapse rates
among smokers with serious psychological distress.
Nicotine withdrawal (NW), a syndrome experienced by 21-50% of abstinent
smokers,12,41 is considered a primary obstacle to quitting smoking,42,43 and a significant
predictor of smoking relapse.44-48 The Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-V)12 characterized NW diagnosis as the presence of four
or more of the following symptoms: 1) irritability, frustration, or anger, 2) anxiety, 3)
difficulty in concentration, 4) increased appetite, 5) restlessness, 6) depressed mood, and
7) insomnia. These symptoms can appear a few hours after quitting smoking49,50 and peak
during the first week of smoking abstinence and persist for 2 to 4 weeks or more.14,44,45
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The emergence of these symptoms is the result of a sudden cessation or reduction of a
tobacco-containing product after a prolonged period of use; and is often followed by
clinical mood changes and impairments in various aspects of functioning.12,13
In addition to the symptoms outlined in the DSM-V diagnosis of NW,12,13 this
syndrome may also take the form of different clinical manifestations such as craving,
fear, anhedonia, constipation, cough, dizziness, increased dreaming, mouth ulcers, and
working memory deficit.14-16 Moreover, reliable effect sizes in studies using a number of
self-report measures (e.g., craving, subjective attentional bias towards smoking cues,
negative affect), cognitive performance tasks (e.g., psychomotor processing, sustained
attention), and physiological parameters (e.g., heart rate, electroencephalography power)
were reported after only 12 hours of tobacco abstinence, indicating that acute NW is not
merely a monotonic phenomenon.17 Hence, given the potential mood changes, functional
impairments, risk for relapse, and the volatile nature of NW,12,17 this syndrome is of a
particular concern to people with mental illness (MI).11,19
Admission of smokers to a smoke-free inpatient facility has been associated with
greater likelihood for NW development.12 This is particularly concerning for patients
with MI, given the mounting trend of smoke-free campus policies in psychiatric
institutions in the U.S..3,24-27,51 The Centers of Medicare and Medicaid Services (CMS)
has also mandated the provision of tobacco treatment during psychiatric hospitalization.28
Quitting tobacco use among people with MI has been linked to better quality of life,
lower likelihood of being discharged against medical advice, and several other positive
physical and psychological health outcomes.9-11 However, moderate to severe NW
symptoms are reported in nearly two-thirds (65%) of psychiatric inpatients,18 which, if
12

left untreated, could potentially lower the likelihood of successful quitting19 and further
compromise the efficacy of psychiatric care.11
Systematic reviews specifically examining NW are scarce and outdated.52,53 To
the best of my knowledge, no systematic reviews of NW among tobacco users with MI
have been published. Therefore, the purpose of this systematic review was to synthesize
the existing NW research literature among tobacco users with MI over the past 12 years,
to outline the findings of the most recent literature addressing NW effects and correlates
in this population, address the gaps in knowledge, and direct future research endeavors.
2.2 Methods
The PsycINFO, PubMed, and CINAHL databases were separately searched using
Boolean logic (e.g., AND, OR) with a combination of medical subject headings, indexed
terms, and keywords. Each database’s subject headings or indexed terms, pertinent to this
systematic review’s topic, were identified before conducting articles search. The
following phrases were used to conduct the search: smoking; cigarettes smoking;
smoking cessation; smoking cessation assistance; nicotine; nicotine use; nicotine
dependence; tobacco; tobacco smoking; tobacco use; tobacco abuse; tobacco use
disorder; AND withdrawal; withdrawal symptoms; nicotine withdrawal; drug withdrawal;
tobacco withdrawal; nicotine withdrawal syndrome; tobacco withdrawal syndrome; AND
psychiatric; psychiatric disorders; psychiatric patients; psychiatric symptoms; mental
disorders; chronic mental illness; chronic mental disorders; mentally ill patients; AND
community mental health; mental health and illness assessment; community; community
dwelling; public; hospitalization; hospital stay; psychiatric hospitalization; psychiatric
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hospitals; psychiatric units; psychiatric institutions; community mental health centers;
community mental health services; tobacco free hospitalization; and smoke free
hospitalization. The Preferred Reporting Items for Systematic Reviews and Meta-analysis
(PRISMA) guidelines and checklist for synthesizing and reporting evidence were adopted
in this systematic review.54
Eligibility for articles selection were restricted to studies: 1) published in peerreviewed academic journals; 2) written in English; 3) using human subjects (non-animal
studies); 4) recruiting adult participants (≥ 18 years of age); and 5) published between
2008 and 2019. The selection process was limited to articles recruiting people with a
history of mental illness or substance use problems, in addition to tobacco, in hospital,
outpatient, or community settings, and addressing nicotine or tobacco withdrawal as a
primary or secondary outcome measure. The search was not restricted by geographic
location. However, research articles using qualitative methods and those tackling nicotine
or tobacco withdrawal using genetic or neurobiological approaches were excluded. Data
extracted from selected articles were obtained by the primary author, and the extracted
data were reiterated by the same author one week later for verification of data accuracy.
Findings are reported based on thematic categories of the selected articles that best reflect
their sample sizes representativeness, setting, and tobacco users’ MI diagnoses.
2.3 Results
Our search yielded 511 articles from the PubMed, CINAHL, and PsycINFO
databases. After screening these articles for the eligibility criteria, a total of 239 articles
were identified. Further, the resulting articles were examined by reviewing the titles
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and/or abstracts for the inclusion of participants with histories of mental illness or
substance use problems and addressing NW as a primary or secondary outcome measure.
A total of 15 articles were included in this systematic review (see Figure 2.1). The
selected articles are compared, and each described by their purpose/aims/hypothesis(es),
design, sample, setting, instrument(s), intervention (if any)/procedure, main findings, and
limitations (see Table 2.1).
2.3.1 Study designs
Six of the 15 studies (40%) adopted cross-sectional research designs; five of the
six studies retrieved their data from secondary sources. Specifically, three studies used
data from at least one nationally-representative survey19,22,55 and two studies used
secondary data from original research.18,56 Another cross-sectional study retrieved data
retrospectively from patients’ chart review.57 Nine studies (60%) used experimental
research designs, two of which used secondary analysis of data from randomizedcontrolled trials (RCT),21,58 and two studies were original RCTs.59,60 One study reported
data from a quasi-experimental design.61 Moreover, two studies used a repeated measures
approach,62,63 and two used pre-posttest designs.64,65
2.3.2 Settings and sample sizes
Selected articles recruited participants from community-dwelling (n = 6),
outpatient (n = 4), and psychiatric hospitalization settings (n = 5). Sample sizes of studies
recruiting from community settings ranged between 81 and 9,913
participants.21,22,55,58,59,66 Sample sizes of participants recruited from MI and/or substance
use outpatient settings ranged from 19 to 225 patients;60-62,65 and sample sizes of studies
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recruiting from psychiatric units in general hospitals or psychiatric in-patient hospitals
ranged between 100 and 754 inpatients.18,56,57,63,64
2.3.3 Participants’ characteristics and psychiatric diagnoses
Studies recruiting from the community included only adult participants (≥18 years
of age) and examined tobacco for current, recent, or at least lifetime use.21,22,55,58,59,66 One
of the six community studies stipulated that participants have at least one previous quit
attempt that lasted for a minimum of 2 weeks.22 All studies recruiting from communitydwelling participants used a self-report interview to establish a psychiatric diagnosis or
problem.21,22,55,58,59,66 Psychiatric problems in these studies included people with posttraumatic stress disorder (PTSD), psychotic (e.g., schizophrenia, schizoaffective,
schizophreniform), mood, anxiety, alcohol use, and substance use disorders.21,22,55,58,59,66
On the other hand, patients recruited from inpatient psychiatric settings had a wide range
of documented psychiatric diagnoses (e.g., psychotic, depressive, adjustment, and
substance use disorders). All participants recruited from inpatient psychiatric settings
were in tobacco-free facilities.18,56,57,63,64 The average reported number of cigarettes
smoked per day by these inpatients ranged between 16 and 24; and all studies, but one,63
indicated the use of NRT during hospitalization.18,56,57,64 However, the majority of the
inpatients demonstrated moderate to severe levels of nicotine dependency.18,56,63 Of note,
the average length of hospitalization ranged from six to 16 days and the majority of
inpatients had co-morbid alcohol or drug use disorders.56,57,64 Similarly, participants
recruited from outpatient psychiatric settings reported smoking approximately 20
cigarettes per day and they had a wide variety of psychiatric diagnoses.60-62,65 It is
noteworthy to mention that one study recruited participants during psychiatric
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hospitalization; however, their intervention took place outside the hospital with an
allowance for participants to smoke.65 Therefore, participants from this study were
considered outpatients.
2.3.4 Experimental design interventions
All nine studies adopting experimental research designs incorporated tobacco use
abstinence as the primary outcome, and the studies took place either in community,
outpatient, or psychiatric hospitalization settings.21,58-65 Three RCTs and one repeated
measures study each randomly assigned their participants into two groups. These four
studies each compared a group of smokers with psychiatric and/or substance use
problems receiving tobacco treatment interventions (e.g., varenicline, NRT, cognitive
behavioral therapy), to a treatment-as-usual or standard treatment group of smokers under
the same tobacco deprivation conditions.58-60,62 Another double-blinded RCT randomly
assigned participants to five intervention groups and one control group, based on a
combination of Bupropion and different forms of NRT administration coupled with
individual counseling.21 The remaining experimental studies (one quasi-experimental,
one repeated measures, and two pre-posttest studies) were one-group designs with
interventions including cognitive behavioral therapy, non-smoking positive experiences,
varenicline, and sessions with tobacco treatment specialists.61,63-65 Participants’ follow-up
for all experimental studies ranged between 1 and 27 weeks.21,58-65
2.3.5 Measures used to assess NW
Several measures were used to assess NW across the 15 selected studies. Seven
studies used the Minnesota Nicotine Withdrawal Scale (MNWS),18,56-58,60,62,66,67 two used
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the Wisconsin Smoking Withdrawal Scale,61,63,68 one study used the Ecological
Momentary Assessment,21,69 one used the Withdrawal Symptoms Checklist-weekly,59,70
and one study used the Computerized Diagnostic Interview Schedule to assess for NW
diagnosis.64,71 In addition, some researchers merely introduced a list of NW symptoms to
participants; one used a list based on DSM-IV criteria and two did not.22,55,65 There was
no similarity in choice of NW measure based on setting (i.e., inpatient, outpatient, or
community). However, studies recruiting from out- and inpatient settings, in general,
used more rigorous measures in assessing NW.18,56,57,60-63
2.3.6 Main findings of NW
For ease of presentation of findings, studies were clustered, based on similarities
in setting or MI diagnoses in addressing NW, into the following categories:
2.3.6.1 Studies using national surveys data across different MI diagnoses
Two studies used nationally-representative data to address NW among tobacco
users with different MI diagnoses.19,55 Smith, Homish, Giovino, and Kozlowski (2014)19
found that tobacco users with MI have higher likelihood to be diagnosed with NW
compared to tobacco users without MI. In fact, they found that MI was responsible for
more than 44% of NW diagnoses in the general population.19 Also, they found that the
likelihood for having NW was greater among tobacco users with psychotic disorders,
mood and anxiety disorders with alcohol and drug use, mood and anxiety disorders, and
alcohol and drug use and antisocial personality disorders, consecutively.19 Similarly,
Weinberger, Desai, and McKee (2010)55 found that greater numbers of NW symptoms
were found among tobacco users with substance or alcohol, mood, or anxiety disorders
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during a quit attempt, compared to tobacco users without these conditions. While both
studies assessed NW using self-report, cross-sectional approaches, the latter study55 did
not examine the severity of NW symptoms, nor include tobacco users with psychotic
disorders.
2.3.6.2 Studies examining NW during psychiatric tobacco-free hospitalization
Six studies examined NW among tobacco users in the context of a tobacco-free
hospitalization. These studies concluded that the following factors were correlated with
greater NW experience during hospitalization: higher psychiatric symptoms severity;
greater nicotine dependence; alcohol and drug use; race (i.e., African American); sex
(i.e., women); timing of receiving NRT; low confidence in quitting; and providing
tobacco treatment medication (i.e., varenicline) and counseling during the hospital
stay.18,56,57,63,64 Five studies used cross-sectional designs,18,56,57,64,65 and only one
examined NW prospectively during hospitalization.63
2.3.6.3 Studies targeting tobacco users with psychotic, mood, or anxiety disorders
Five studies examined NW among tobacco users with psychotic, depressive, or
anxiety disorders. Piper, Cook, Schlam, Jorenby, and Baker (2011)21 found that,
compared to tobacco users who did not have anxiety disorders, greater pre-quit NW was
found among those with panic attacks, generalized anxiety, or social anxiety disorders.
Further, a significant positive association was found between having a post-traumatic
stress disorder (PTSD) and NW symptoms.22,59 Similarly, depression was associated with
greater likelihood of having NW and NW-related relapse during a quit attempt.22,58
Lastly, Schuster et al. (2017)61 noticed that improvements in NW symptoms in a sample
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of smokers with schizophrenia, schizoaffective, and bipolar disorders enhanced tobacco
use abstinence, compared to those who did not have improvements in NW symptoms
prior to a quit day.
2.3.6.4 Studies targeting tobacco users with substance use disorders
Two studies, primarily studied the association between NW and substance or
alcohol use. Reid et al. (2008)60 found that smoking cessation counseling and NRT
administration decreased NW severity in a sample of tobacco users with substance abuse
in general. On the other hand, Streck, Heil, Higgins, Bunn, and Sigmon (2018)62
indicated that opioid-dependent smokers have greater NW severity compared to smokers
without substance use disorders.
2.4 Discussion
The purpose of this systematic review was to synthesize, and outline NW
correlates found in the literature among tobacco users with MI. The search yielded 15
research articles from the PubMed, CINAHL, and PsycINFO databases. The selected
articles represented tobacco users with MI or substance use problems in community,
outpatient, and inpatient psychiatric tobacco-free hospital settings. Also, the selected
articles varied in designs, participants’ diagnoses and characteristics, measures of NW,
interventions tested, and findings related to NW. In summary, NW among tobacco users
with MI is correlated with the following factors: 1) MI diagnoses (with varying severities
across diagnoses); 2) psychiatric symptoms severity; 3) sex; 4) race; 5) previous or
concurrent alcohol and drug use; 6) nicotine dependence; 7) timing of offering and use of
NRT during psychiatric tobacco-free hospitalization; 8) confidence in quitting; 9) pre20

quit attempt anxiety and depression levels; and 10) pharmacological intervention (i.e.,
varenicline use). Below is a more detailed description of selected studies based on
representativeness of studies’ samples, settings, and MI diagnoses.
2.4.1 Nationally-representative studies
In a secondary analysis of data from two large national surveys including
participants with and without MI, Smith et al. (2014)19 classified MI diagnoses into the
following categories: no disorder; internalizing disorders (i.e., past year mood and
anxiety disorder); externalizing disorders (i.e., past year alcohol use disorders and drug
use disorders, and lifetime antisocial personality disorder); internalizing and externalizing
disorders; and psychotic episode or disorder. MI was responsible for 44.4% of the NW
syndrome diagnoses in the total sample; and that across all MI categories, there was
greater likelihood to be diagnosed with NW syndrome, compared to smokers without
MI.19 In addition, the relative risks of having NW for participants with MI, compared to
those without MI, were 1.37, 2.37, 3.12, and 3.45 for externalizing disorders,
internalizing disorders, internalizing and externalizing disorders, and psychotic disorders,
respectively.19 The symptom profiles of NW were, however, consistent across MI
categories, and NW-related distress was higher among these categories, compared to
people without MI.19 Higher relative risk of experiencing NW among patients with
psychotic, mood, and anxiety disorders than those with substance use and anti-social
personality disorders is consistent with the affective nature of NW symptomatology (e.g.,
anxiety, restlessness, anger, depression) dictated by the DSM-IV-TR and DSM-IV
criteria.12,13 This affective nature is usually characteristic in these disorders, compared to
the latent process of disinhibition usually encountered in drug and alcohol use and
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personality disorders.19,72 Similarly, Weinberger et al. (2010)55 conducted a secondary
analysis of data on a nationally-representative sample (n=8,213) from the National
Institute of Alcohol Abuse and Alcoholism (NESARC) study. Having a current diagnosis
of mood, anxiety, alcohol use, or substance use disorders was associated with greater
number of reported NW symptoms during a quit attempt, compared to people without
these conditions.55 Further research is required to understand how affective symptoms
observed in internalizing disorders may impede quit attempts among people with MI by
virtue of greater NW severity.
2.4.2 Psychiatric tobacco-free hospitalization
Soyster, Anzai, Fromont, and Prochaska (2016)18 employed a secondary data
analysis to examine the characteristics and correlates of NW in a sample of 754
psychiatric inpatients from 3 mental health units in San Francisco. Using a general linear
regression model, researchers indicated that being a woman, African American, having
greater psychiatric symptoms severity, greater nicotine dependence, and having a
diagnosis of both alcohol and other drug use disorders were associated with greater NW
severity.18 Furthermore, 65% of patients experienced moderate to severe NW
symptoms.18 Another study conducted in an inpatient psychiatric setting examined the
associations between NW and NRT.20 In this study, NW severity among patients
receiving NRT on the unit was significantly greater than those receiving NRT at
admission and those not provided NRT. Specifically, NW symptoms, such as
restlessness, anxiety, anger, and depression, were significantly higher among patients
receiving NRT on the unit, versus those receiving NRT at admission.20 Furthermore, in a
multivariate regression model to examine the predictors of NW severity during
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psychiatric hospitalization, it was found that lower confidence in quitting and receiving
NRT on the unit predicted greater NW symptoms severity.20 Delayed administration of
NRT during hospitalization was associated with greater NW symptoms.20 This finding is
particularly important among patients with higher likelihood of having greater NW
symptoms, such as being African American.18 However, Soyster et al. (2016)18 stated that
people of an African American ethnicity were less likely to be offered NRT, given that
these patients did not refuse NRT at high rates. Greater attention is required to address
disparities in providing smoking cessation services during psychiatric hospitalization.
Three more studies examined NW in the context of smoke-free hospitalization.
Leyro et al. (2013)56 characterized clinical management of tobacco withdrawal and
dependence in a sample of 324 psychiatric inpatients, almost half of whom had unhealthy
levels of alcohol consumption and/or illicit drug use. They found that offering NRT at
admission was associated with greater likelihood of using it, compared to offering it later
during hospitalization. This further supports the practice of adopting tobacco cessation
treatment at the outset of psychiatric hospitalization, given that it not only increases the
likelihood of using NRT,56 but also decreases NW symptoms severity during
hospitalization.57 Leyro et al. (2013) also indicated that NRT use was higher among those
with greater NW symptoms, tobacco dependence, and depressive symptoms.56
Interestingly, patients with psychotic disorders were more likely to use a combination of
NRT products (i.e., nicotine gum and patch) compared to patients with other psychiatric
diagnoses.56 This is consistent with Smith et al. (2014)’s66 conclusion that psychotic
patients experience greater NW severity compared to other psychiatric diagnoses. Pachas
et al. (2012)63 also found that NW symptoms among patients with stable schizophrenia,
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who have moderate-to-severe nicotine dependence, progressively decreased over a 12week period after providing varenicline and cognitive behavioral therapy during
psychiatric tobacco-free hospital stay. This also resulted in a significant (47% of the
sample; n=112) 2-week, biochemically-verified tobacco abstinence after 3 months.63
However, NRT use was not reported in the paper. Finally, Shmueli, Fletcher, Hall, Hall,
and Prochaska (2008)64 studied whether smoking abstinence related to tobacco-free
psychiatric hospitalization was associated with changing thoughts about quitting in a
sample of 100 smokers. Prior to hospital discharge, there was a significantly higher
perception of successful quitting and lower expectation of difficulty quitting smoking
compared to those reported at admission.64 Interestingly, NW did not seem to affect
patients’ desire to quit smoking, expectancy in successfully quitting, and staying quit in
the period from hospital admission to discharge.64
2.4.3 Tobacco users with psychotic, mood, or anxiety disorders
Piper et al. (2011)21 compared the NW characteristics of 579 community-dwelling
participants who ever met life-time criteria for an anxiety diagnosis to 891 smoking
counterparts who did not meet criteria. Before embarking on a quit attempt, participants
who ever experienced a panic attack reported greater pre-quit negative affect and
withdrawal and increases in post-quit intensity of cessation fatigue.21 In addition,
participants who ever met criteria for generalized anxiety or social anxiety disorders
reported higher pre-quit levels of cravings, negative affect, and withdrawal symptoms,
and greater quit-day cessation fatigue.21 Ever experiencing generalized anxiety disorder,
social anxiety disorder, or panic attack predicted poor smoking cessation outcomes
almost up to 8 weeks after starting the quit attempt.21 Also pertinent to anxiety disorders,
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Weinberger, Maciejewski, Mckee, Reutenauer, and Mazure (2009)22 conducted a
secondary data analysis of sex differences in NW among a sample of 816 communitydwelling participants who made a quit attempt in the past lasting at least for 2 weeks.
Investigators examined sex differences with regard to psychiatric diagnoses and found
that, regardless of gender, having a life-time panic disorder increased the odds of
experiencing recurrent NW symptoms by 3 times during multiple quit attempts.22 In
terms of smoking cessation outcomes, researchers found that women who had at least one
PTSD in their lifetime were nearly 5 times more likely to relapse due to NW compared to
men with the same condition.22 Also, with regard to the association between PTSD, NW,
and anxiety sensitivity (AS), Asnaani, Farris, Carpenter, Zandberg, and Foa (2015)59
found that the association between AS and PTSD was only significant at low levels of
NW severity.59 Arguably, in a randomized, double-blinded study, Cosci, Bertoli, and
Abrams (2013)73 found no effect of NW on AS between groups receiving, versus not
receiving, NRT. However, participants in this study did not have a diagnosis of panic
disorder.73 Finally, Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults
were found correlated to NW symptoms.74,75 In fact, tobacco users with ADHD
experience higher NW symptoms severity during early abstinence, compared to those
without ADHD.76 However, ADHD medication was found to alleviate NW symptoms
and cotinine levels in adult ADHD smokers, compared to those receiving placebo.77 In
summary, the effects experienced by people with a history of anxiety disorders may be
related to similarities in the symptoms usually encountered by people with these
diagnoses and the diagnostic criteria of NW (e.g., depression, anxiety, restlessness,
irritability),12 in addition to the proposed reduced coping skills to the challenge of
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quitting faced by these smokers.21 Future research is needed to address whether reducing
anxiety symptoms pre-quit would yield better smoking cessation outcomes in this
population.
As with the case of psychotic and anxiety disorders, several examinations also
demonstrate higher NW with depressive symptoms. Reid and Ledgerwood (2016)58
found that having higher levels of depression before a quit attempt affected the patterns
of NW and urges to smoke over a 5-week period. Similar to this findings, another study
confirms that having a history of life-time major depressive disorder is associated with a
2.5 times increased risk to relapse due to NW.22 Alternatively in an examination of
negative mood, depressive symptoms, and major depressive episodes in 179 smokers
with a history of major depression, Kahler et al. (2002)78 found that short and long-term
smoking abstinence was associated with enhancement in depressive symptoms, but the
incidence of major depressive episodes in these patients was independent of smoking
abstinence.78 Finally, varenicline was found effective in achieving 14-day smoking
abstinence in a sample of 135 outpatients with psychotic or mood disorders.61 This
duration of abstinence was predicted by prior alcohol dependence, lower expectation of
peer support on quitting, high vigilance and low reaction time variability, and
improvement in NW prior to quitting day.61 Thus, from these studies it may be surmised
that future research needs to investigate the effects of therapeutic interventions to reduce
pre-quit depressive symptoms on smoking cessation outcomes.
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2.4.4 NW and tobacco users with alcohol or substance use disorders
A number of studies have demonstrated an important relationship in substance use
effect on NW. For instance, in a multi-site RCT among 225 smokers, from community
substance abuse rehabilitation centers, Reid et al. (2008)60 found that NW and cravings
decreased significantly in the treatment group (compared to control) and that craving for
the designated abused substance simultaneously decreased with smoking reduction.
Another study found that alcohol use disorder increased the odds of experiencing any
NW symptoms during a quit attempt by 2.5 times.22 However, men were found to have
2.5 times greater odds for relapse due to NW than women, if both had a life-time alcohol
abuse or dependence.22 Furthermore, in comparing 47 opioid-dependent smokers and 25
smokers without substance use disorder diagnoses on daily basis for a 2-week period,
Streck et al. (2018)23 found that after adjusting for age, education, number of regularsmoking years, CO level, and nicotine dependence, opioid-dependent smokers reported
higher NW severity than non-substance use disorder smokers. Moreover, females in the
non-substance use disorder group demonstrated steeper declines in nicotine craving over
the study period, compared to females in the opioid-dependent group.23 Nevertheless, the
association between NW and patients with substance use disorders other than opioid and
alcohol, to the best of our knowledge, has not been studied before in the literature and
definitely merits systematic investigation. There remains a dearth of knowledge about
how different substance use dependence levels affect NW experience and relapse
outcomes. Considering the relatively high rates of substance use among patients with
MI,32 it is unknown whether substance use across different psychiatric diagnoses yields
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different NW frequencies, severities, and relapse outcomes. Well-designed moderation
studies can help scrutinize these relationships.
2.5 Limitations
The findings in our systematic review had some limitations that are worth
mentioning. The heterogeneity of studies was our major limitation. That is, experimental
and non-experimental studies were included, with different sample sizes, settings,
interventions, and participants’ diagnoses and tobacco use characteristics. This may affect
the overall generalizability of our findings. Among experimental studies, RCTs, quasiexperimental, pre-posttest, and repeated measures research designs were included. While
some studies included control or comparison groups, many did not, dictated by design.
On the other hand, many non-experimental studies adopted cross-sectional and secondary
analysis of data approaches, which may have resulted in missing significant factors
associated with NW. In addition, inconsistencies in treatment modalities (e.g.,
varenicline, cognitive behavioral therapy, and NRT), participants’ milieus (i.e.,
community-dwelling, inpatient, or outpatient settings) and participants’ characteristics
(e.g., different MI diagnoses) across studies may affect our results. Moreover, the
trajectories of NW were not studied by different MI diagnoses. Noticeably, NW was not
addressed for tobacco users with MI using more than one form of tobacco (e.g.,
smokeless tobacco), which represents a major a gap in the literature. Last, the majority of
studies did not assess tobacco abstinence rates and NW-related relapse over time for
more than 6 months.
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2.6 Conclusion
Considering the high prevalence of tobacco use among people with MI, the
purpose of this systematic review was to synthesize the research findings related to NW
over the past 12 years. Several NW correlates among people with MI were identified
across different settings and among different MI diagnoses. Identifying NW in this
population can help nurses and other health care professionals, in community, inpatient
and outpatient settings, identify patients of higher risk for developing NW and NWrelated distress. The findings of this systematic review can also help tobacco treatment
specialists develop and tailor evidence-based practices for patients to reduce barriers to
tobacco use quit attempts. NW is a barrier that hinders a smoker’s ability to quit tobacco
and promotes relapse. More research is needed to scrutinize the nature and correlates of
this phenomenon for more evidence-based recommendations, and guidance in tailoring
effective interventions.

29

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness.
Authors
Okoli, AlMrayat,
Shelton, and
Khara
(2018)57

Purpose/Aims or
hypotheses
To examine the
association between
providing NRT upon
admission with the
motivation to quit
and the severity of
NW symptoms, in the
context of smoke-free
hospitalization.

Design
Crosssectional;
retrospective
chart review.

Sample

Setting

Two-hundred
and fifty-five
adult patients,
87-90% of
whom admitted
involuntarily
,who were
assessed by a
mental health
professional.

Inpatient,
tobacco-free
psychiatric
hospitalization.

Instrument(s)
Demographics.
Tobacco use characteristics.
Timing of providing NRT:
admission vs. on the unit vs.
not provided.
Period between admission and
receiving NRT.
The motivation ruler – used to
assess patients’ perceived
importance, confidence, and
readiness to quit smoking or
tobacco use.
Stage of change in tobacco
use – patients were classified
into 2 groups: precontemplator/contemplator
and preparers/action.
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The MNWS.

Intervention(if any)
and/or Procedure
A retrospective analysis
of data retrieved from
medical records between
January and December
2016 in a psychiatric
hospital in Kentucky.
Upon admission, every
patient was assessed by a
tobacco treatment nurse
for NW, readiness to
quit, and other aspects of
patients’ tobacco use.
Then, the nurse provides
practical counseling to
encourage the patient to
engage in the tobacco
treatment services.

Main Findings

Limitations

* Patients with cognitive
disorders had the highest
frequency of reporting at
least 1 NW symptom, and
patients with substance use
disorders had the greatest
NW severity.

Psychiatric
symptoms
severity was not
assessed.

* NW severity among
patients receiving NRT on
the unit was significantly
greater than those receiving
NRT at admission and
those not provided NRT.
Specifically, patients
provided NRT on the unit
had higher mean scores of
depression, anger, anxiety,
and restlessness, compared
to those not receiving NRT
at admission.
* Lower confidence in
quitting and receiving NRT
on the unit (vs. at
admission) was associated
with greater NW severity in
a multivariate regression
analysis.

NW symptoms
severity was not
assessed
throughout the
period of
hospitalization.
The effect of comorbid
psychiatric
disorders was
not assessed.
The sample
included only
15% of the
tobacco users
admitted to the
hospital.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Soyster,
Anzai,
Fromont, and
Prochaska
(2016)18

To examine the
characteristics and
correlates of NW
severity among
patients with MI
during psychiatric
hospitalization.

Crosssectional;
secondary
analysis of
data.

A total of 754
psychiatric
inpatients from
seven smokefree units at 3
hospitals in San
Francisco.
Participants
were adults
smoking at least
5 cigarettes per
day with no
overly
aggressive,
somnolent, or
disorganized
behaviors.

Inpatient.

FTND.
MNWS.
Electronic version of the
Mini International
Neuropsychiatric Interview
(eMINI) – to assess for
current psychiatric
disorders and previous
trauma exposure.
The Behavior and
Symptom Identification
Scale (BASIS-24) – used to
assess past week overall
psychiatric symptom
severity score.

A secondary data analysis
from the baseline survey
of an interventional
study. The analyses were
performed prior to
introducing the
intervention.

* Having higher levels of
nicotine dependence and prior
use of NRT was associated
with greater likelihood to be
offered NRT. However, being
African American and being
older were associated with
lower likelihood of being
offered NRT.
* Patients with no prior use of
NRT, lower nicotine
dependence, and milder
cigarette craving were more
likely to refuse NRT.
* The prevalence of NW
symptoms severity was
described as follow: less than
1%, complete absence; 10%
as slight; 24% as mild; 40%
as moderate; and 25% as
severe.
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* A general linear regression
model has indicated that
greater NW severity was
associated with being a
woman, African American,
greater psychiatric symptoms
severity, greater nicotine
dependence, and having a
diagnosis of both alcohol and
other drug use disorders.

The absence of
randomization
of the covariates
increased the
ecological
validity of the
findings.
However, it
prevented
deriving causal
mechanisms.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Piper, Cook,
Schlam,
Jorenby, and
Baker
(2011)21

To examine how NW,
dependence,
treatment response,
and cessation success
relate to specific
anxiety diagnoses:
Generalized Anxiety
Disorder (GAD),
Social Anxiety
Disorder (SAD), and
panic attacks.

Secondary
analysis of
data of a
randomizedcontrolled
trial.

A secondary
analysis of data
including 1504
smokers who
reported
smoking 10 or
more cigarettes
per day for the
past 6 months
with a
motivation to
quit. Smokers
also were mild
alcohol drinkers
with no history
of a psychotic
or eating
disorder.

Community
dwelling.

FTND.
The Wisconsin Inventory
of Smoking Dependence
Motives (WISDM).
Ecological Momentary
Assessment (EMA) –
used to assess for various
smoking-related measures
for the past 15 minutes,
including cessation
fatigue.
The World Mental Health
Survey Initiative, version
of the Composite
International Diagnostic
Interview – used to
provide, past year and
ever, diagnoses for
various diseases,
including SAD, GAD,
and Panic disorder.
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Cessation outcomes at 8
weeks and 6 months (e.g.,
CO levels).

At baseline, participants
underwent CO, vital
signs, and medical
history screening with the
world mental health
survey initiative version
of the composite
international diagnostic
interview.
Participants were then
double-blinded and
randomized into one of 6
treatment conditions:
bupropion SR; nicotine
lozenge; nicotine patch;
nicotine patch + nicotine
lozenge; bupropion SR +
nicotine lozenge; or
placebo. All medications
were provided for at least
12 weeks post-quit.
The EMA was reported
twice a day (once before
going to bed and once
after waking).
The EMA data of
cessation fatigue and
withdrawal measures
were analyzed and
depicted on a graph
illustrating patients’ prequit level, pre-quit slope,
and post-quit slope.
All participants received
6, 10-20 minutes,
individual counseling
session in social support,
coping, and problem
solving.

* Five hundred and seventynine participants ever met
criteria for an anxiety
diagnosis, and 205 met that
criterion for the past 12
months. The comparisons
were made relative to
participants with no anxiety
diagnosis (n=891).
Compared to participants with
no anxiety diagnosis:
1. Smokers who experienced a
panic attack anytime in the
past reported higher levels of
pre-quit negative affect and
withdrawal and increases in
post-quit slope of cessation
fatigue.
2. Smokers who ever had
GAD reported greater levels
of pre-quit cravings, negative
affect, withdrawal symptoms,
and more intense pre-quit and
quit-day cessation fatigue.
3. Smokers who ever had SAD
reported higher pre-quit levels
of cravings, negative affect,
withdrawal symptoms, and
cessation fatigue, in addition
to greater quit-day cessation
fatigue.
* In general, and after
adjusting for age, gender, race,
and treatment, ever having a
panic attack, multiple anxiety
diagnoses, SAD, or GAD
predicted poor smoking
abstinence outcomes over an
8-week period.

The study sample
was highly
motivated and
willing to engage
in a smoking
treatment plan.
The baseline
assessment did
not account for
current
symptomatology.
Other anxiety
disorders were
not accounted for
(e.g., obsessivecompulsive
disorder, specific
phobias).
Patients were not
randomly
assigned to the
treatment groups.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Weinberger,
Maciejewski,
Mckee,
Reutenauer,
and Mazure
(2009)22

To examine whether
the interaction
between gender and
psychiatric diagnosis
(major depressive
disorder, panic
disorder, PTSD, and
alcohol use or
dependence) has an
effect on reporting
NW, and relapse in
response to NW.

Crosssectional;
secondary
analysis of
data of a
subsample of
the National
Comorbidity
Survey.

A total of 816
communitydwelling
participants
who reported
current tobacco
use with 1≥
attempts to quit
smoking, which
lasted for at
least 2 weeks.

Community
dwelling.

Modified version of the
Composite International
Diagnostic Interview –
used to assess the
presence of psychiatric
disorders.
Number of quit attempts.
Any withdrawal
symptom – participants
were provided a list of
NW symptoms (e.g.,
difficulty sleeping,
cravings, headache) and
asked to report if they
experienced any
symptom in that list.

A retrospective analysis
of data from a study
conducted between 1991
and 1992 by the
National Co-morbidity
Survey (CNS).
Analyses were adjusted
for demographic
variables (i.e., age, race,
income, education,
marital status).

* Approximately equal
proportions of men and women
reported experiencing NW
during their quit attempts
(women, 68%; men, 67.7%).
* Approximately equal
proportions of men and women
reported relapsing to smoking,
seeking relief of NW (women,
60%; men, 59%).
* The number of life-time quit
attempts was not different
between genders.
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Longest period of
withdrawal (in days).

* Women with major
depressive disorder and alcohol
abuse/dependence reported
longer periods of experiencing
NW compared to men.

Any recurring
withdrawal symptoms –
whether NW symptoms
experienced during
multiple attempts to quit.

* Regardless of gender, having
a history of alcohol use
disorder increased the odds of
experiencing any NW during a
quit attempt by 2.5 times.

Relapse to alleviate
withdrawal symptoms.

* Regardless of gender, having
a life-time panic disorder
increased the odds of
experiencing recurrent NW
symptoms by 3 times for
multiple quit attempts.
* Women with life-time major
depression disorder reported
experiencing 2.7 times greater
NW recurring symptoms
compared to men with the same
condition.
* Regardless of gender, having
a history of life-time major
depressive disorder was
associated with increasing the
risk to relapse due to NW by
2.5 times.
* Men reported 2.5 times
greater the odds to relapse due
to NW than women, if both had
a life-time alcohol
abuse/dependence.

Recall bias
because, NW was
assessed
retrospectively.
Inclusion to the
study was
restricted by
those whose quit
attempts lasted at
least for 2 weeks.
Information
regarding severity
of alcohol
abuse/dependence
and psychiatric
symptoms were
not assessed.
Other psychiatric
illnesses with
high relevance to
smoking were not
assessed (e.g.,
schizophrenia).

* Women who had life-time
PTSD were nearly 5 times
more likely to relapse due to
NW than men with the same
condition.

34

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Asnaani,
Farris,
Carpenter,
Zandberg, and
Foa (2015)59

To examine the
relations between
Anxiety Sensitivity
(AS) (i.e., having a
tendency towards
greatly misinterpreting
internal anxietyrelated sensations),
NW, and PTSD
symptoms among
smokers seeking
tobacco treatment.
To examine whether
higher NW severity
moderates the
association between
AS and PTSD
symptom severity.

Randomizedcontrolled
trial.

A total of 117
adult
participants who
smoked at least
10 cigarettes per
day and have a
diagnosis of
PTSD.
Participants did
not have
substance use
disorders other
than nicotine,
and no
psychosis or
prominent
suicidal
ideations.

Community
dwelling.

Anxiety Sensitivity Index
(ASI).
Withdrawal Symptoms
Checklist – Weekly
(WSC-W) – used to
assess the severity of NW
over the past week.
PTSD Symptom Scale
Interview (PSS-I) – used
to assess the severity of
PTSD symptoms. It
includes a total score and
3 subscales: reexperiencing, avoidance,
and hyperarousal.
CO levels.

At baseline (week 0),
participants were
screened for PTSD
symptoms using the
structured clinical
interview and were
randomized into standard
smoking cessation
treatment (varenicline
and supportive
counseling) and standard
smoking cessation with
PTSD treatment
(varenicline, supportive
counseling, and
prolonged exposure
therapy). The treatment
sessions lasted for 12
weeks.
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Participants were
assessed for the battery of
instruments at baseline,
12 weeks, and 27 weeks
later.
Cross-sectionally random
sampling (without
replacement) of cases for
analyses included all
three times of
assessment.

* Adjusting for gender, time
of assessment, expired CO,
and negative affect, the main
effects of AS and NW were
significant on total PTSD
symptom severity, and the
interaction of both, AS and
NW, was significant as well.

Nicotine
dependence
was not
included in the
analyses
because it was
assessed only
at baseline.

* The moderations models
revealed that the association
between AS and PTSD was
only significant at low levels
of NW severity.

The varying
levels of AS
were not
assessed.
Other
cognitiveaffective risk
processes were
not controlled
for, which
might have
affected PTSD
symptoms
severity.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Streck, Heil,
Higgins,
Bunn, and
Sigmon
(2018)62

To examine the effect
of NW between
smokers with Opioid
Dependency (OD)
and smokers without
co-morbid Substance
Use Disorder (SUD),
and to examine
whether gender
moderates NW.

Secondary
analysis of
data from 5
studies; twogroup,
repeated
measures.

Forty-seven OD
adult smokers
who used
methadone or
buprenorphine
and who reported
smoking at least
10 cigarettes per
day, and 25 nonSUD adult
smokers who
also smoked at
least 10
cigarettes per
day.

Outpatient.

FTCD.
MNWS – the desire to
smoke item (i.e., craving)
was analyzed separately.

A retrospective analysis of
data gathered from 3
studies.
Participants visited the
laboratory for 14
consecutive days, and
nicotine abstinence was
biochemically verified.
Participants completed the
FTCD at baseline and the
MNWS in every visit.
Participants selected if
more than 85% of the
biochemically-verified
samples indicated
abstinence.

* Before embarking on the quit
attempt, and after adjusting for
age, education, number of
years of regular smoking, CO
level and nicotine dependence,
OD smokers reported higher
NW severity than non-SUD
smokers.
* There was a significant
decline in NW for both groups
over the period of 14 days.
However, NW was not
different between the groups.
* Smokers with OD had higher
desires to smoke at baseline,
compared to those without
SUD.
* There was a significant time
× gender × group interaction in
craving over the 14-day period.
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* Compared to males, females
showed a significant group ×
visit interaction, with females
in the non-SUD group
demonstrating a steeper decline
in tobacco craving relative to
females in the OD group.

Participants’
anticipation of
increases in
anxiety or
withdrawal
might have
affected NW
during study
period.
Small sample
size.
Timing and
doses of
medication
among
participants in
the OD group
was not
assessed.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Reid and
Ledgerwood
(2016)58

To examine whether
the effect of elevated
depression scores
prior to a smoking
quit attempt predicts
patterns of NW and
urges to smoke, in a
group of nicotinedependent smokers
undergoing smoking
cessation treatment.

Secondary
analysis of a
randomized
controlled
trial.

A total of 81
smokers who
did not have
severe or
uncontrolled
psychiatric
disorders or
current
substance
dependence
issues.

Community
dwelling.

Structural Clinical
Interview for DSM-IV-TR
– to assess for suicidality,
psychosis, and substance
use.
Smoking history.
FTND – administered at
baseline and every week.
Beck Depression
Inventory, second edition
(BDI-II) – participants
were dichotomized into
high and low depressive
symptoms – administered
at baseline and every
week.
Questionnaire of Smoking
Urges -Brief –
administered at baseline
and every week.
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MNWS – administered at
baseline and every week.
CO – administered twice
daily at baseline and
throughout the treatment
weeks.

Participants attended the
treatment clinic for 5
weeks, twice daily, 5 days
per week. The first week
was for baseline
measurements and to
prepare participants for
quitting.

Linear mixed model analyses
were performed for all the
analyses.

Participants were then
randomized into standard
care and rewardmotivated treatment
groups.

* Reporting higher depression
at the onset of treatment was
associated with greater NW
throughout treatment.

* The main effects of
depression scores and time
were significant on NW
symptoms severity.

* The main effect of the
treatment condition on NW
was insignificant.
* Main effects of depressive
scores and time revealed
significant effect on smoking
urges.
* Interaction of depressive
scores and time on NW was
also significant.
* Reporting higher levels of
depression was associated
with increased levels in urges
to smoke during the first week
followed by progressive
reduction in those urges in the
remaining treatment period.
* No significant effect of
treatment condition was found
on urges to smoke.

Small sample
size.
The highdepression
(n=18) and
low-depression
(n=63) groups
were unevenly
distributed.
Finding were
pertinent to
smokers
reporting
depression
rather than
smokers with
major
depressive
disorder.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Smith,
Homish,
Giovino, and
Kozlowski
(2014)19

To compare the
severity and
likelihood of having
NW syndrome across
mental illness
diagnoses and in
relation to those
without MI.
To compare NW
symptoms among MI
diagnoses.
To estimate the
proportion of NW
syndromes caused by
MI.
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To estimate whether
smokers with MI
have higher levels of
motivation to quit
and greater quitting
attempts, compared
to smokers without
MI.
To examine the
influence of NW and
nicotine dependence
on cessation efforts
among smokers with
MI.

Crosssectional;
secondary
analysis of
data from 2
national
surveys.

Study 1:
Wave-1 of the
National
Epidemiologic
Survey on
Alcohol and
Related
Conditions
(NESARC). A
sample of 9,913
individuals who
reported smoking
100 cigarettes
during their
lifetime,
including last
year. Data was
collected
between 20012002.
Study 2:
Data was
retrieved from a
2-wave national
telephone survey
of U.S. smokers
25 years of age
or more between
May 2004 and
March 2005. A
total of 751
smokers were
included in the
analyses.

Community
dwelling.

Study 1:
1. Mental illness. MI was
assessed using the
Alcohol Use Disorder and
Associated Disabilities
Interview Schedule.
2. Nicotine Withdrawal.
NW was assessed based
on the DSM-IV criteria
for its diagnosis.
3. Withdrawal-Related
Distress. This distress was
assessed using surveyorsgenerated questions.
Study 2:
1. Nonspecific
Psychological Distress –
using Kessler’s K6
screening tool.
2. Nicotine Dependence –
using the Heaviness of
Smoking Index (HSI).
3. Nicotine Withdrawal –
using the MNWS.
4. Quitting Motives, quit
attempts, and quit success
– using surveyors
generated questions.
Successful quitting was
defined as having 30 days
of abstinence from all
tobacco products.

A retrospective analysis
of data was employed. In
order to make a
theoretically-sound
diagnostic groupings of
MI, researchers classified
MI diagnoses in their
samples into the
following categories:
1. No disorder.
2. Internalizing disorder
– past year mood and
anxiety disorder.
3. Externalizing disorder
– past year alcohol use
disorders and drug use
disorders and lifetime
antisocial personality
disorder.
4. Internalizing and
externalizing disorders.
5. Psychotic episode or
disorder.

* Among all MI categories,
there was greater likelihood to
be diagnosed with NW
syndrome, compared to
smokers without MI. The
relative risks (RR) were 1.37,
2.37, 3.12, and 3.45 for
externalizing disorders,
internalizing disorders,
internalizing and externalizing
disorders, and psychotic
disorders, respectively.
* Mental illness was
responsible for 44.4% of the
NW syndrome diagnoses of the
total sample.
* compared to smokers with no
MI, and after adjusting for
sociodemographic variables, the
RRs of having NW-related
distress were 1.26, 1.65, 1.97,
and 2.47 for externalizing,
internalizing, internalizing and
externalizing, and psychotic
disorders, respectively.
* Symptoms profiles of NW
were consistent across the MI
categories. However, anxiety
was a better marker for
internalizing disorders, and
restlessness was a better marker
for internalizing and
externalizing disorders.
* Smokers with nonspecific
psychological distress were
more motivated to quit, reported
more severe NW, have higher
nicotine dependence, and were
less likely to successfully quit
compared to those without
nonspecific psychological
distress.
* Nonspecific psychological
distress and quit success were
mediated by NW and
dependence.

Due to using
cross-sectional
design in study
1, the
occurrence and
time course of
NW was never
determined.
Measures of
smoking
cessation were
not
biochemically
verified.
A significant
number of
smokers with
MI might not
have
participated in
the surveys in
the first place.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Reid et al.
(2008)60

Researchers
hypothesized that a
smoking cessation
program, given to
participants in
community substance
abuse rehabilitation
centers, will be
acceptable by
participants, effective
in promoting smoking
abstinence, and not
worsening the
concurrent drug
alcohol treatment.

Multi-site
Randomized
controlled
trial.

A total of 225
participants (153
in the smoking
cessation
treatment group
and 72 in the
treatment-asusual group).
All participants
met substance
dependence
criteria, smoked
around a pack of
cigarettes, and
have moderate
to high levels of
nicotine
dependence.

Outpatient

Baseline:

For the treatment group:

1. Demographics
2. Smoking status.
3. Exhaled carbon CO
results.
4. Urine cotinine results.
5. Fagerstrom nicotine
tolerance questionnaire.
6. Smokers’ belief
questionnaire.
7. reasons for quitting
questionnaire.
8. Abbreviated version of
the addiction severity
index.
9. Urine drug screen
results.
10. alcohol breathalyzer
results.
11. Vital signs.

1. Smoking cessation
counseling of 9 sessions,
which was tailored for
patients undergoing
substance use treatment.
Sessions started 1 week
before the target quit day
and continued for 6
weeks after the quit day.

Weekly and follow-up at
weeks 13 and 26:
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1. self-reported average
cigarettes per day.
2. Exhaled CO levels.
3. compliance with
smoking cessation and
drug rehabilitation
treatment.
4. Modified MNWS.
5. Urine drug screen.
6. Alcohol breathalyzer
test.
7. self-reported substance
abuse.
8. vital signs, weight,
adverse events, and
concomitant medication
information.

2. NRT, consisted of 2
forms of transdermal
nicotine patches (21 and
14mgs), which were
tapered over time.

* Adherence to taking the
NRT was highest in the first 3
weeks after the quit date.
* Adherence to NRT use was
higher among patients in the
methadone program compared
to patients in the nonmethadone program.
* Smoking abstinence was 1011% during weeks 2-7 in the
treatment group/
* Smoking abstinence rates
were 5.5% and 5.7% at weeks
13 and 26 for the treatment
group, respectively. Compared
to 0% and 5.2% for the control
groups at weeks 13 and 26,
respectively.
* During treatment period, the
treatment group had around
75% reduction in the number
of daily smoked cigarettes and
a decrease in CO levels,
compared to the control group.
At weeks 13 and 26, patients
in the treatment group had
significantly less cigarettes per
day compared to control.
* NW and cravings decreased
significantly in the treatment
group, compared to control.
* Drug and alcohol abstinence
rates between treatment and
control groups were similar
over the course of smoking
cessation, with no main effect
of treatment condition.
* Fewer number of cigarettes
smoked per day were
associated with lower craving
for the primary abused
substance.

Most
participating
sites (80% of
the sample)
adopted
methadonebased treatment
programs.
Applicability of
the program
was considered
unfeasible for
many sites that
chose to drop
from this study.
Contribution in
the reduction in
smoking and
smoking
abstinence rates
were not
separately
attributed to
counseling or
NRT
intervention.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Schuster et al.
(2017)61

To identify predictors
of smoking abstinence
among smokers with
bipolar or
schizophrenia, who
were treated with a
combination of
cognitive behavioral
therapy and
varenicline for 12
weeks.

Quasiexperimental;
secondary
analysis of
data.

One hundred and
fifty-three
outpatients from
10 community
mental health
centers in 6
states. Patients
had a DSM-IVTR diagnosis of
schizophrenia,
bipolar, or
schizoaffective
disorders.
Patients were
clinically stable
for the past
month, smoked
at least 10
cigarettes per
day, and had an
expired CO
levels of at least
9 ppm.

Outpatient.

Demographics.
Cognitive performance
(e.g., accuracy, vigilance,
speed of processing).
Treatment characteristics
(e.g., antipsychotic
regimen).
Smoking characteristics
(e.g., expired CO levels,
FTND, Wisconsin
Smoking Withdrawal Scale
[WSWS]).
Smoking environment
(e.g., number of people
smoking in household,
support from others in
quitting smoking).
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Psychopathology (e.g.,
Barrett impulsiveness
scale, brief psychiatric
rating scale, and the
schedule for assessment of
negative symptoms).
Physical health (BMI and
Framingham score).

Open-label varenicline
started at 0.5mg once
daily, which was
gradually increased to
1mg twice daily for 11
weeks. In addition,
cognitive behavioral
therapy sessions of 1
hour given on weekly
basis for 12 weeks. Quit
day was determined
after 4 to 5 weeks of
taking the medication.

* Around 50% of the sample
managed to achieve 14 days of
biochemically-verified
continuous abstinence at week
12 of the study.
* A multivariate model
identified the following
predictors of a 14-day
abstinence in our sample:
number of cigarettes per day,
prior alcohol dependence,
lower expectation of peer
support on quitting, high
vigilance and low reaction
time variability, and
improvement in NW prior to
quitting day.

Lack of control
group.
Findings
cannot be
generalized to
patients with
psychiatric or
medical
instability or
have substance
use disorders.
All patients
included in
analyses
completed at
least 3 weeks
in the study.
Therefore,
study findings
cannot be
generalized to
patients not
completing at
least 3 weeks
of treatment.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Leyro et al.
(2013)56

1. Characterizing
clinical management
pertinent to tobacco
withdrawal and
dependence among
smokers hospitalized
with MI.
2. Determination of
provider practices and
patient utilization of
NRT predictors in
terms of smokingrelated,
demographics,
psychiatric, and
substance use factors.

Crosssectional;
secondary
analysis of
data;
exploratory
design.
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A total of 324
psychiatric
inpatients from
2 hospitals.
Patients
reported
smoking for 21
years, with an
average of 19
cigarettes per
day. They also
reported
moderate levels
of nicotine
dependence and
almost half of
the sample
having
hazardous
alcohol
consumption
and/or current
illicit drugrelated
problems.

Inpatient,
smoke-free
psychiatric
hospitalization.

Demographics.
Tobacco use
characteristics (e.g., age of
onset, years smoking).
The seven-item MNWS.
Heaviness of smoking
index.
Authors-developed NRT
questionnaire.
The 10-item Center for
Epidemiologic Studies
Depression Scale (CES-D10).
The 10-item Alcohol Use
Disorders Identification
Test (DAST).
Mental health
characteristics (e.g.,
Global Assessment
Functioning [GAF] score,
reason for hospitalization).

Charts of newly
admitted patients were
reviewed by research
staff. Eligible patients
who are interested in
participation were
approached and
consented.

* The majority of participating
patients (73%) were offered
NRT at admission.
* Around 50% of participants
used NRT during
hospitalization.
* Participants who were
offered NRT at admission
were more likely to use it,
compared to participants who
were offered NRT later during
hospitalization.
* Timing of offering NRT was
undiscriminating regardless of
demographics, psychiatric
diagnosis, hospital site,
substance use characteristics,
and length of hospital stay.
* Compared to patients who
did not use NRT, patients who
used NRT had higher
depressive symptoms, were
heavier smokers, and had
greater NW.
* Unlike nicotine gum, prior
use of nicotine patch was
related to NRT patch use
during hospitalization.
* Participants’ belief that NRT
was helpful for quitting,
decreases NW, and represents
a substitution when he/she
cannot smoke were associated
with greater likelihood of
using NRT.
* Patients with psychotic
disorders were more likely to
use a combination of NRT
products (i.e., gum and patch),
compared to patients with
mood disorders or other
psychiatric diagnoses.

Cross-sectional
design.
Limited
generalizability
due to limited
geographical
disposition of
the study.
Since patients
were given the
freedom to
choose their own
NRT type, heavy
smokers may not
have chosen a
combination of
NRT products,
regardless of
their
effectiveness.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Weinberger,
Desai, and
McKee
(2010)55

1. Comparing smokers
with current axis I
psychiatric disorders to
smokers without, in
terms of different NW
aspects.
2. comparing the NW
experience among
smokers with comorbid
psychiatric and
substance/alcohol use
disorder and smokers
with a single
psychiatric or
substance/alcohol use
disorders.

Nationallyrepresentative
survey;
secondary
analysis of
data.

A subsample of
current smokers
(8,213) from the
National
Institute of
Alcohol Abuse
and Alcoholism
(NESARC)
study.
Participants
were adults (≥
18 years of age),
were at least
high school
graduates, with
53% having
current nicotine
dependence.

Community
dwelling.

Demographics and
smoking information
(e.g., marital status, age of
smoking onset).
Psychiatric diagnosis;
using the Alcohol Use
Disorder and Associated
Disabilities Interview
Schedule – Version for
the DSM-IV.
NW; by reporting any of
the DSM-IV-TR signs
and symptoms of NW
over the past 12 months
(yes/no).
Tobacco use relapse
because of NW.

Secondary analysis of
data.

* Having a current mood,
anxiety, alcohol use, or drug
use disorder was associated
with younger age of smoking
onset, higher likelihood of
reporting nicotine
dependence, and reporting at
least one NW symptom.

Cross-sectional
data.

* Having a current diagnosis
of mood, anxiety, alcohol use,
or substance use disorders
was associated with greater
number of reported NW
symptoms during a quit
attempt, compared to people
without these conditions.

The following
pertinent
information
were not
assessed: NW
symptoms
severity,
number of quit
attempts,
duration of quit
attempts, and
smoking
cessation
treatment
utilized.
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* Comorbidity between mood
or anxiety disorders and
alcohol use or substance use
disorders was found
insignificant in reporting NW,
compared to smokers without
comorbidity.
* NW-related distress,
discomfort, and NW-smoking
relapse were found more
likely among smokers with
current mood, anxiety, or
substance use disorders, but
not alcohol use disorder.

Self-report.
Retrospective
recall bias of
NW.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Shmueli,
Fletcher, Hall,
Hall, and
Prochaska
(2008)64

To examine whether
thoughts about
quitting smoking were
associated with
smoking abstinence
related to psychiatric
smoke-free
hospitalization.

Pre-posttest
design;
secondary
analysis of
data.

A total of 100
patients who
smoked more
than 100
cigarettes over
their lifetime,
and who smoked
at least one
cigarette the
week preceding
hospitalization.
Patients were
hospitalized, on
average, for 7.5
days.

Inpatient,
smoke-free
psychiatric
hospitalization

The Smoking History
Questionnaire.
FTND.
The Computerized
Diagnostic Interview
Schedule-IV (CDIS-IV).
The Secondhand Smoke
Exposure Survey.
The Stages of Change
Scale.
The Commitment to
Abstinence Scale.
Chart review (e.g., length
of stay, NRT use).

First assessment was
conducted within 48
hours of admission; and
the second assessment
was conducted before
patients’ discharge. After
hospitalization, patients
were followed up at 1
week, 1 month, and 3
months.

* Compared to assessment at
hospital admission, patients
had both statistically
significant higher perception
of successfully quitting and
lower expectation of difficulty
in quitting smoking prior to
hospital discharge.
* Psychiatric diagnoses (62%
of patients were diagnosed
with NW using the CDIS-IV)
did not seem to affect patients’
desire to quit smoking,
expectancy in successfully
quitting, and staying quitted;
from hospital admission to
discharge.
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* Compared to the number of
cigarettes smoked before
hospitalization, this number
was significantly lower at the
3-month follow up. However,
all patients reported returning
to smoking.
* After hospital discharge,
48% of participants reported
conducting a quit attempt.

Recruitment
from 1 clinical
site.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Keizer et al.
(2012)65

To describe the
feasibility of an
intervention, based on
the association of
temporary smoking
abstinence with
positive experiences.

Pre-posttest.

Nineteen
smoking patients
admitted to a
tobacco-free
psychiatric
hospital in
Geneva,
Switzerland.
Participants
were generally
heavy smokers,
consuming
around 1 pack
per day.

Outpatient.

Cigarettes per day (CPD).
HSI.
Stage of motivation to
quitting.
Self-efficacy about
smoking cessation.
7 withdrawal symptoms.
Expired CO levels.

Patients left the hospital in
the morning; were
encouraged to stay smokefree, and were engaged in
positive experiences
associated with nonsmoking, such as outdoor
restaurant lunch, informal
discussion about the
smoking abstinence
experience, group sessions
with a tobacco treatment
specialist, thermal baths,
and afternoon tea with
music. NRT was offered
free of charge during
hospitalization and during
intervention.
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Participants returned in at
night. CO levels was
measured in the morning,
afternoon, and the next
morning of the
intervention day.
Follow up, after 1 week,
including assessment of
CPD over the past week
after the intervention, HSI,
and stage of motivation
and self-efficacy.

* Around 80% of participants
were abstinent at 10-hour
period and 47% were abstinent
the next morning.

Lack of a
control group.

* CO levels decreased
significantly throughout the
intervention day.

Non-validated
instruments.

* Reporting of NW was low.
Actually, around one-third of
participants reported perceived
benefits of abstinence with
regard to concentrating,
depression, craving, and
anxiety.
* Significant reduction in the
number of smoked cigarettes
was found 1 week before and
after the intervention.

Sample size.

Short period of
observation.

Table 2.1 Characteristics of Studies Addressing Nicotine Withdrawal among Tobacco Users with Mental Illness
(continued).
Pachas et al.
(2012)63

To prospectively
evaluate smoking
outcomes, adverse
events, and
psychiatric symptoms
among patients with
stable schizophrenia
during treatment with
varenicline and
cognitive behavioral
therapy.

One-group
repeated
measures.

A total of 112
adult patients
with stable
schizophrenia.
Participants were
on average 47
years of age,
smoked more
than 1 pack of
cigarettes per
day, and had
moderate to
severe nicotine
dependence.

Inpatient
psychiatric
hospitalization.

Baseline:
1. Smoking and medical
history.
2. Expired CO.
3. FTND.
4. Cotinine and drug
screen test results.
Weekly assessment:
1. Self-report smoking
behavior.
2. End-expiratory CO
measurement.
3. NW, using the WSWS.
4. Calgary Depression
Scale for schizophrenia.
Baseline and end-oftreatment assessment:
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1. Brief psychiatric Rating
Scale.
2. Schedule for the
Assessment of Negative
Symptoms.

Varenicline 0.5mg once
daily, increased
gradually to 1mg twice
daily for 11 weeks. In
addition, 1-hour session
of cognitive behavioral
therapy on weekly basis.
The quit day was set
between weeks 4 and 5.

* From week 1 to week 12 or
early termination, there was
significant improvements in
NW symptoms and psychosis
ratings.
* Similarly, the repeated
measures analyses revealed
increases in abstinence rates
and decreased NW symptoms.
* The progressive increase in
abstinence rates was associated
with progressive decreases in
depressive and CO levels as
well.

Absence of
control group.
Limited
statistical
power related
to sample size.
Around onethird of
participants
dropped out
early.

* By the end of week 12,
around 47% of participants
achieved 2 consecutive weeks
of smoking abstinence that was
biochemically verified. Also, at
the same timepoint, 34% of
participants achieved 4 or more
consecutive weeks of,
biochemically-verified,
smoking abstinence.

Abbreviations used across studies: NRT=Nicotine Replacement Therapy; NW=Nicotine Withdrawal; MI=Mental Illness; FTND/FTCD=Fagerstrom Test for Nicotine Dependence/Fagerstrom Test for
Cigarettes Dependence; CO=Carbon Monoxide; PTSD=Post Traumatic Stress Disorder.

Screening

Primary search: using Boolean logic, the PubMed, CINAHL,
and PsycINFO databases were searched using a combination
of medical subject headings, indexed terms, and keywords

511 articles identified
Eligibility
criteria:

Eligibility

Titles and/or abstracts
with the Methods section
were reviewed. The
following articles were
excluded:
Neurobiological or
genetic studies.

Published
between 2008
and 2019.
Written in
English.
239 articles
identified

Published in peer
reviewed
journals.
Recruiting
human subjects.

Qualitative studies.
Systematic reviews.

Adult (≥18 years
of age)
participants

Studies not addressing
NW as a primary or
secondary outcome
measure.
Studies recruiting
participants with no
previous mental or
substance use problems.
Included

≥

Identification

Figure 2.1 A Diagram of Articles Selection Process.

Duplicate articles.

15 articles selected
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CHAPTER 3. THE PSYCHOMETRIC PROPERTIES OF THE MINNESOTA
TOBACCO WITHDRAWAL SCALE AMONG PATIENTS WITH MENTAL
DISORDERS79
3.1 Introduction
People with serious mental illness (SMI) are disproportionately affected by
tobacco use compared to the general population.1 About 21% to 59% of people with SMI
are current tobacco users.2-6 In particular, those diagnosed with schizophrenia, mood,
anxiety, and substance use disorders have the highest smoking prevalence rates.66,80
During the first decade of the 21st century, there was a significant decline in the sales and
rates of cigarette smoking in the general population.81,82 On the other hand, the rates of
smoking among people with SMI remain high, with an increasing gap in smoking
prevalence between people with and without SMI in the general population.82 In fact,
people with SMI consume around 44% of all cigarettes smoked annually in the United
States.7 Consequently, and in addition to the negative social and economic effects of
smoking, people with SMI have higher risk for cancer, heart, and lung diseases, have 10
to 25-year shorter life expectancy, and constitute more than one-third of the U.S. annual
smoking-attributed mortalities.1,8 Therefore, it is crucial to identify and assess factors that
may compromise tobacco treatment (TT) among people with SMI.
An important factor that often hinders successful TT is the nicotine withdrawal
(NW) syndrome. This syndrome is a set of symptoms appearing within 24 hours after an
abrupt cessation or reduction in the consumption of tobacco-containing products, for
those using nicotine on a daily basis for at least a couple of weeks.12 The Diagnostic and
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Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), requires four or more of
the following eight symptoms for a NW syndrome diagnosis: dysphoric/depressed mood,
insomnia, irritability/frustration/anger, anxiety, difficulty concentrating, restlessness, or
increased appetite/weight gain.12 Around 65% of psychiatric inpatients report moderate to
severe NW, which has been correlated to gender (i.e., women), polysubstance use, and
being African American.18 In fact, people with SMI have higher NW symptom severity
during a quit attempt as compared to the general population;19 which may compromise
successful quit attempts and the efficacy of the provided psychiatric care, if left
untreated.11,19 Given the current trend towards tobacco-free psychiatric hospitalizations in
the United State,25-27,51 it is important to have valid and reliable tools for capturing NW
syndrome among patients with SMI.
Identifying and treating NW during a tobacco-free psychiatric hospitalization
could enhance the provision of psychiatric care and may increase the likelihood of
engaging in TT among patients with SMI. The Minnesota tobacco withdrawal scale
(MTWS), previously named the Minnesota nicotine withdrawal scale,83,84 is a widely
used instrument for detecting NW. It has been translated into several languages, applied
in different populations, used to assess the efficacy of nicotine replacement therapy
(NRT) and withdrawal symptomatology to smokeless tobacco, and has also been used to
predict smoking relapse.62,85-88 Compared to other scales used to measure NW such as the
mood and physical symptoms scale,89 the Shiffman-Jarvik scale,90 the Wisconsin
withdrawal scale (WWS),68 and the cigarette withdrawal scale (CWS), the MTWS
showed high sensitivity in detecting certain NW symptoms (irritability, difficulty
concentrating, craving, restlessness, and anxiety), but low sensitivity to depression and
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insomnia after 24 hours of tobacco use abstinence.91 When test-retest reliability and
Cronbach’s alpha were compared between the MTWS, the CWS, and the WWS in an
internet cohort sample, the MTWS showed a high Cronbach’s alpha coefficient (≥0.85);
and a moderate intraclass correlation coefficient (r = 0.71) compared to the CWS (r =
0.79) and the WWS (r = 0.80).92 Validity testing of the MTWS was examined through
confirmatory factor analysis, which concluded that a unidimensional model of the 8-item
MTWS best fitted their data, which was derived from three separate clinical trials.93
Among outpatient clients with schizophrenia who demonstrated a stable
psychiatric state, Weinberger et al. (2007)94 examined the internal consistency and testretest reliability of the MTWS and the Tiffany questionnaire for smoking urges (TQSU).
Researchers found that the internal consistency reliability coefficient of the MTWS was
0.88 compared to 0.79 and 0.88 for the TQSU factor 1 (urges to smoke in response to
positive reinforcement) and factor 2 (urges to smoke in response to negative
reinforcement), respectively. Also the test-retest reliability coefficient was 0.58 for the
MTWS compared to 0.65 and 0.69 for the TQSU factors 1 and 2, respectively.95
However, the validity and reliability of the MTWS has not been examined extensively
among patients with SMI in a hospitalized tobacco-controlled setting.
The purpose of this study was to examine the psychometric properties of the
MTWS among patients with SMI in the context of a tobacco-free psychiatric
hospitalization. The specific aims of this study were to:
(1) test the reliability of the MTWS (i.e., internal consistency/item analysis reliabilities)
and to (2) support the MTWS’s validity by:
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(a) hypothesizing that patients with higher tobacco consumption would report
higher NW severity on the MTWS; and
(b) examining exploratory factorial analysis of the MTWS.
3.2 Methods
3.2.1 Sample and setting
Data were obtained from Eastern State Hospital (ESH), a 239-bed State-operated
and owned psychiatric hospital serving 50 counties in Kentucky. Starting January 1st,
2016, ESH enhanced its existing inpatient services to include evidence-based TT
services96,97 in compliance with the inpatient psychiatric facility quality report
requirements.28 These TT services are comprised of assessing patients’ tobacco use
characteristics (e.g., tobacco type used and number of packs used per day), offering TT
and practical counseling, and administering Food and Drug Administration (FDA)
approved medication. In addition, the services included monitoring and management of
NW by a qualified registered nurse for all tobacco users able to engage in this treatment
service. Since the ESH is covered by a 100% tobacco-free campus policy, patients are
unable to leave the units to use any tobacco products as per the policy.
3.2.2 Design
This study was a secondary analysis of data from a retrospective review of
medical records from 255 admissions to ESH between January 1st, 2016 and December
31st, 2016. Of the total 2751 admissions in 2016, 1073 patients were current tobacco
users. Two hundred and fifty-five (23.8%) of these tobacco users were able to respond to

50

the administration of the MTWS. Those who did not respond were unable to do so
because of their psychiatric symptom severity, stayed in the hospital for a short duration,
or refused to respond. Data were derived from the records of tobacco-using psychiatric
patients, 18 years of age and older, who engaged in the TT services in the specified time
period. The original study examined the relationships between the provision of NRT at
admission, patients’ motivation to quit smoking, and NW severity.99 Approval for this
study was obtained from the University of Kentucky medical institutional review board
(Exemption Certification for Protocol No. 17-0064-X2B).
3.2.3 Measures
Demographics and clinical characteristics. Patients’ demographics retrieved from
medical records included age, race (i.e., White vs. non-White), sex (i.e., male vs. female),
and education level (i.e., less than high school vs. high school/GED vs. associate degree
or higher). In addition, the following clinical variables were also retrieved from the
medical records: psychiatric diagnosis, duration of hospitalization (in days), tobacco use
type (i.e., cigarettes vs. non-cigarettes), substance use history (i.e., yes vs. no), cigaretteequivalents per day (CPD), and the use of NRT during hospitalization (yes vs. no). CPD
was calculated based on converting different tobacco products to the cigarette equivalent
based on approximate nicotine content, such that 1 can of chew tobacco was equivalent to
1 pack of cigarettes, 1 cigar was equivalent to 4 cigarettes, and 1 can/tin of moist tobacco
was equivalent to 2.5 packs (i.e., 50 cigarettes/day equivalent).81,100 One individual was
an e-cigarette user for whom the amount of nicotine consumed was not available in the
charts; thus, for the cigarette equivalent per day calculations, it was conservatively
assumed that the individual used a pack of cigarettes per day. For ease of analysis,
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patients’ discharge diagnoses were categorized into clinically-driven psychiatric groups;
including psychotic (i.e., schizophrenia, schizoaffective, psychotic disorder not otherwise
specified etc.), mood and anxiety (i.e., major depressive disorder, bipolar disorder, posttraumatic stress disorder etc.), substance use (i.e., alcohol, cocaine, marijuana, opiate
etc.), or other (i.e., personality, malingering, cognitive, or altered mental status not
otherwise specified) disorders. Patients with psychotic disorders have been grouped
separately in the literature.19 Patients with mood and anxiety disorders were grouped
together because they were postulated to represent a higher-order factor (i.e.,
internalizing disorder).101 Similarly, patients with substance use disorders were grouped
separately because they were postulated to represent another higher-order factor (i.e.,
externalizing disorders).101
The Minnesota Tobacco Withdrawal Scale. The MTWS is a self-report 8-item
scale based on the diagnostics criteria for NW in the DSM-IV-TR (i.e.,
irritability/frustration/ or anger, anxiety, difficulty concentrating, increased appetite,
restlessness, depressed mood, and insomnia), in addition to craving.13,83 For this study,
the MTWS scores were obtained from patient record review. Item responses ranged
between 0 (i.e., no symptoms) and 4 (i.e., severe symptoms), with a total potential score
of 32. The MTWS was administered to patients as close to admission as possible.
However, there were instances, in which, at admission, patients were unwilling or unable
(due to psychiatric symptom severity) to provide responses to the MTWS. In such cases,
the MTWS was administered by nursing staff at a time when the patient was stable
enough to provide an adequate response (often within 1 to 4 days of admission). In fact,
only 2 (0.8%) patients were assessed on the day of admission, 106 (41.5%) within 1-2
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days of admission, 55 (21.6%) within 3-4 days of admission, and 92 (36.1%) after 5 days
of admission.
3.2.4 Data analysis
Means (M) and standard deviations (SD) were used to describe interval- and ratiolevel variables, and frequencies and percentages (%) were used to describe ordinal and
nominal level variables. Differences in patients’ demographics, duration of
hospitalization, type of tobacco used, substance use history (yes vs. no), MTWS scores,
and the administration of NRT (yes vs. no) were examined by the CPD values (i.e., above
and below the median, 20.00) using Chi square for nominal and ordinal level variables,
and t-test or analysis of variance (ANOVA) for interval and ratio level variables. SPSS
version 24 was used for all analyses, and α was set at 0.05.
3.2.5 Reliability testing
Cronbach’s alpha was calculated to assess the internal consistency reliability of
the MTWS. In addition, item analysis was further employed to assess the homogeneity of
the instrument in terms of its item-total and inter-item correlations. Item-total and interitem correlations between 0.2 and 0.8 are desirable. However, correlation coefficient
values more than 0.8 are considered redundant.102 Test-retest reliability examination was
inappropriate due to the rapidly changing nature of NW over a relatively short period of
time,13 and the limited number of readmissions in our sample (n=22).
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3.2.6 Validity testing
Hypothesis testing and exploratory factor analysis were employed to assess the
construct validity of the MTWS among patients with SMI during a psychiatric smokefree hospitalization. First, based on the evidence in the literature confirming that
individuals experiencing higher NW symptom severity after 24 hours of abstinence also
report higher consumption rates of nicotine,103,104 we hypothesized that patients with
higher CPD scores would report higher NW severity on the MTWS (as a proxy of the
amount of nicotine consumption). To test this hypothesis, a general linear regression
model was used to examine whether the CPD score was an independent associative factor
with the MTWS scores, adjusting for the dosage of NRT (none vs. 14mg vs. 21mg), race,
duration of hospitalization, and discharge diagnosis. These covariates were included for
control in the regression model due to their association with NW as previously evident in
the literature. Specifically, the duration of hospitalization is a significant correlate of
tobacco use in this population,105 the administration of NRT is associated with lesser NW
severity scores among patients with SMI during hospitalization,99 and African American
patients with SMI have higher NW severity compared to their Caucasian counterpart.18
Lastly, patients with different SMI diagnoses have varying probabilities of being
diagnosed with NW syndrome.19 Because the MTWS scores were skewed, we performed
regression analyses with both raw and log-transformed MTWS values.
Second, an exploratory factor analysis was used to examine the structure and
construct validity of the MTWS. The suitability of the data for factor analysis was
verified using the Kaiser-Mayer-Oklin and the Bartlett’s sphericity tests. Distinct
dimensions/factors of the instrument were identified using the scree plot and eigenvalues
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of 1 and more, and each dimension’s items were distinguished by 0.4, or more, Varimaxrotated loading values when applicable.106
3.3 Results
3.3.1 Sample characteristics
Our sample consisted primarily of White (89.4%) males (55.7%), with a mean age
of 42 years (SD=14). On average, patients had a 16-day hospitalization period and a 3.2
(SD=4.2) score on the MTWS. Patients primarily were diagnosed with psychotic (38.4%)
or mood and anxiety (31.8%) disorders, had at least a high school/GED education level
(72.6%), were cigarette smokers (89.4%) who consumed on average 23.7 (SD=16.7)
CPD, had a substance use history (69.5%), and had received NRT during their current
hospitalization (92.5%). Moreover, males and White patients were more likely to have
CPD values of more than 20 compared to females and non-White patients (Ps=0.11 and
0.027, respectively). Furthermore, patients with greater MTWS scores were more likely
to have CPD values of more than 20 (P<0.001), as were patients who were non-cigarette
users (P<0.001) (see Table 3.1).
3.3.2 Reliability testing
The reliability analysis yielded a Cronbach’s alpha coefficient of 0.763, interitem
correlations coefficient of 0.393, and item-total correlations between 0.291 and 0.691.
Item-item correlations, between 7 items (excluding the craving item), ranged between
0.21 and 0.717. However, craving was poorly correlated with insomnia, difficulty
concentrating, and weight gain/increased appetite in our sample, with correlation
coefficient values of 0.183, 0.177, and 0.081, respectively. Anyhow, the overall
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Cronbach’s alpha of the instrument did not decline below 0.698 when any of its items
were deleted, including the craving item (see Table 3.2).
3.3.3 Validity testing
A general linear regression model, using data from 255 patients was used to
examine whether the CPD scores would be independently associated with higher MTWS
scores. The general regression model identified race (i.e., being non-White) (β: 0.240, CI:
0.277-1.104, p-value = 0.001) and the CPD values (β: 0.147, CI: 0.000-0.015, p-value =
0.048) as independent, statistically significant associative factors with the MTWS scores.
That is, considering the dosage of NRT (i.e., none vs. 14 mg vs. 21mg), race,
hospitalization period (in days), and the psychiatric diagnosis at discharge as adjusted
covariates, the mean score of the MTWS would increase by 0.147 for each 1 unit increase
on the CPD scores. No other variables were significantly associated with the MTWS
scores, and the overall model explained 8.7% of the total variance in the dependent
variable (see Table 3.3). We performed the same analysis with the MTWS scores that
were log-transformed and still had the CPD as a statistically significant associative factor
in both models.
The exploratory factor analysis identified one factor with an eigenvalue of 3.920,
which explained 49% of the total variance in the MTWS scores. Most of the items loaded
significantly on this factor with item loadings ranging between 0.452 and 0.835.
However, the item measuring cravings to smoke in this population had the least loading
on this factor (0.377) (see Table 3.4). The fitness of the data for factor analysis was
confirmed by the Kaiser-Mayer-Oklin statistic of 0.865 and the Bartlett’s test of
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sphericity (P-value < 0.001). No rotation of loadings was performed due to lacking more
than one factor.
3.4 Discussion
The purpose of this study was to examine the psychometric properties of the
MTWS among patients with SMI during a tobacco-free psychiatric hospitalization.
Although the MTWS has been extensively validated in other samples, it has not been
examined among psychiatric inpatients during a tobacco-free hospitalization. Our
findings indicate adequate validity and reliability psychometric properties of the MTWS
in this population in terms of its internal consistency, homogeneity of items, and
measurement of the intended construct. These findings have some important implications
for TT in this population.
We found that all items of the MTWS had fair to moderate correlations with the
total scale score; and that all items representing the diagnostic criteria of NW, as
indicated by the DSM-IV-TR, demonstrated good item-to-item correlation coefficients.
Also, the Cronbach’s alpha correlation coefficient of the scale exhibited good internal
consistency when any of its items were deleted. Comparable findings were reported
previously in the literature among patients with SMI. For example, in a sample of 151
psychiatrically stable smokers with schizophrenia, a 0.88 Cronbach’s alpha coefficient
was obtained on the MTWS, as compared to 0.90 in a control group of smokers without
schizophrenia (n=181).95 Similarly, in an internet-based study involving participants from
the United States, Canada, and Europe, the Cronbach’s alpha coefficient of the MTWS in
2043 ex-smokers was reported to be 0.85.92 The relatively lower Cronbach’s alpha
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observed in our sample (i.e., 0.76) as compared to prior studies may be due to
differences in sample characteristics. For example, as compared to our sample of acutely
hospitalized psychiatric patients, a study by Weinberger et al. (2007)107 was based on a
sample of psychiatrically-stable outpatients and the study by Etter and Hughes (2006)92
was derived from a sample of non-psychiatric patients. Thus, the internal consistency
finding of the MTWS in our sample seems adequate to support the homogeneity of the
scale for acutely hospitalized psychiatric patients during a tobacco-free hospitalization.
Furthermore, we hypothesized and found, through adjusted multivariate
regression analyses, that greater tobacco consumption was associated with higher NW
symptom severity in our sample. This association may lend support for the construct
validity of the MTWS. The construct validity of the MTWS has also been scrutinized
previously using hypotheses testing. Evidence to support the validity of the MTWS was
also demonstrated in other studies when it was used to test the differences in NW
symptoms severity between recent (≤31 days) and long term (32-365days) ex-smokers,
recent ex-smokers (≤31days) and daily smokers, and recent (≤31 days) ex-smokers and
never smokers.92 The finding in our sample, along with results found in the
aforementioned study, further strengthens the validity of the MTWS in measuring the
construct of NW. Moreover, a unidimensional construct was identified through our factor
analysis of the MTWS, as indicated by an eigenvalue of 1 and more, and a scree plot (not
shown). Nonetheless, an exploratory factor analysis of a Korean translated version of the
MTWS suggested that this scale may have two dimensions (i.e., the early-occurring
disturbances in mental functioning, and the disturbances in physiological functioning and
late-occurring disturbances in mental functioning dimensions), that explained 66% of the
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variation in the NW scores.108 Yet, other studies have found that the MTWS is
unidimensional.92,93 Hence, more research may be warranted to confirm the
dimensionality of the instrument.
Several limitations should be taken into consideration in properly interpreting the
findings of our psychometric analysis. Primarily, this study was limited by the fact that
some potential factors affecting NW were not included in our regression model (e.g. cooccurring substance use). Second, the effect of classifications and dosages of the
prescribed antipsychotic medication during hospitalization on NW were not available and
could not be addressed in this study. Third, the data for this secondary analysis was based
on a convenience sample of participants who were willing and able to provide responses
on the MTWS. This sample represented only about 23.8% of all tobacco users who were
admitted to the hospital during the data collection time frame, which may limit the
generalizability of the findings. Fourth, our sample had relatively low average scores on
the MTWS with 27.8% reporting no NW symptoms. These low scores may have been a
result of patients being administered NRT at admission per hospital protocol. This
administration of NRT potentially mitigated the severity of NW in our sample and may
not represent the typical profile of NW among psychiatric patients who do not receive
NRT during hospitalization. Fifth, the measurement of the MTWS occurred at variable
times after admission, which may have skewed the MTWS scores. Hence, it is possible
that alpha and factor analyses may have exaggerated the internal consistency and factor
loadings because of the distribution of the MTWS. This limitation is particularly of note
because the eigenvalues on the scree plot were very close to having a second dimension
of the scale (0.969). Moreover, because of the low subsample proportion of the diagnostic
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groups, we were unable to examine the validity and reliability of the MTWS for
individual diagnoses; however, future studies with robust sample sizes should be
considered to assess the reliability and validity of the MTWS among different diagnostic
groups. Finally, the adequacy of the MTWS in measuring NW has not been examined
longitudinally throughout the period of hospitalization. Future studies may examine
changes in NW scores over time to better understand the time-course of the symptom
severity among patients with SMI during a tobacco-free hospitalization.
3.5 Conclusion
Addressing factors, such as NW, which may hinder engagement in TT among
people with SMI remains a critical area of research. Evaluating the psychometric
properties of the MTWS can lend confidence in its use as an assessment tool for
assessing NW by nurses and other health professionals. We found that the MTWS
demonstrated reliable and valid psychometric properties for measuring NW among
patients with SMI during a psychiatric tobacco-free hospitalization. This instrument may
be recommended in clinical practice to identify patients with high NW severity, in order
to take necessary measures in managing withdrawal during a tobacco-free hospitalization.
Future research should examine the efficacy in measuring NW in this population over an
extended period of hospitalization. Such research is crucial in addressing ways to curb the
hidden tobacco use epidemic among people with SMI.
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Table 3.1 Differences in Sample Demographics and Clinical Variables by Cigarette Equivalents per Day (N=255)
Mean ± SD or N (%)
Variable

Whole sample
255 (100%)

CPDa 0-20
180 (70.6%)

CPDa>20
75 (29.4%)

P-Value

42 ± 14

42.5 ± 14.3

40.9 ± 13.5

0.405

Males
Females

142 (55.7%)
113 (44.3%)

91 (50.6%)
89 (49.4%)

51 (68%)
24 (32%)

White
Non-White

228 (89.4%)
27 (10.6%)

156 (86.7%)
24 (13.3%)

72 (96%)
3 (4%)

Diagnosis categories
Psychotic disorders
Mood and anxiety
disorders
Substance use disorders
Other disorders

98 (38.4%)
81 (31.8%)
40 (15.7%)
36 (14.1%)

71 (39.4%)
58 (32.2%)
25 (13.9%)
26 (14.4%)

27 (36%)
23 (30.7%)
15 (20%)
10 (13.3%)

Hospitalization period

16.2 ± 28.2

15.1 ± 25.9

18.8 ± 33.3

0.339

3.2 ± 4.2

2.6 ± 3.2

4.7 ± 5.6

<0.001*

Age (in years)
Sex

0.011*

Race

0.027*
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MTWSb scores

0.680

Education level
Less than high school
70 (27.5%)
46 (25.6%)
24 (32%)
Highschool/GED
82 (32.2%)
60 (33.3%)
22 (29.3%)
Associate degree or
103 (40.4%)
74 (41.1%)
29 (38.7%)
higher
Tobacco use form
Cigarettes
288 (89.4%)
169 (93.9%)
59 (78.7%)
Non-cigarettes
27 (10.6%)
11 (6.1%)
16 (21.3%)
Substance use history
Yes
171 (69.5%)
121 (69.5%)
50 (69.4%)
No
75 (30.5%)
53 (30.5%)
22 (30.6%)
Nicotine replacement therapy
Yes
236 (92.5%)
164 (91.1%)
72 (96%)
No
19 (7.5%)
16 (8.9%)
3 (4%)
a Cigarettes equivalents per day. b Minnesota Tobacco Withdrawal Scale. * Statistically significant at α equals 0.05.

0.565

<0.001*

0.988

0.176

Table 32.2 Item-total and Inter-item Correlations for the MTWS (N=255)
Corrected
Craving
item-total
correlation
MTWS Item
Craving
0.291
Depressed mood/sad
0.548
Insomnia/sleep problems/awakening at night
0.576
Anger/irritable/frustrated
0.691
Anxious/nervous
0.636
Difficulty concentrating
0.589
Restlessness
0.689
Increased appetite/hungry/weight gain
0.312
* Less than 0.20. Cronbach’s alpha = 0.763. Interitem correlations = 0.393.

1.00
0.243
0.183*
0.288
0.223
0.177*
0.260
0.081*

Depressed
mood/sad

1.00
0.423
0.465
0.527
0.415
0.413
0.264

Insomnia/
sleep
problems/
awakening
at night

1.00
0.530
0.438
0.514
0.602
0.292

Anger/
irritable/
frustrated

1.00
0.717
0.519
0.638
0.229

Anxious/
nervous

1.00
0.476
0.584
0.210

Difficulty
concentrating

1.00
0.625
0.330

Restlessness

1.00
0.350

Increased
appetite/
hungry/
weight
gain

1.00

Cronbach’
s alpha if
item
deleted
0.853
0.730
0.732
0.698
0.711
0.732
0.702
0.761
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Table 3.3 Summary of Multivariate Regression Model (N=255)
Variable
B
β

Confidence Interval
(CI)

p-Value
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CPD

0.008

0.147

(0.000-0.015)

0.048*

Dosage of NRT
Not given NRT
(reference)
14mg
21mg or more

--0.115
0.192

--0.059
0.119

--(-0.244-0.474)
(-0.116-0.500)

--0.529
0.221

--0.690

--0.240

--(0.277-1.104)

--0.001*

-0.001

-0.032

(-0.006-0.004)

0.667

Race
White (reference)
Non-White
Hospitalization period (in
days)

Discharge diagnosis
Other disorders
--------(reference)
0.188
0.114
(-0.165-0.541)
0.295
Depressive disorders
0.055
0.033
(-0.294-0.404)
0.756
Psychotic disorders
0.175
0.083
(-0.233-0.583)
0.399
Substance use disorders
Dependent variable: Nicotine withdrawal severity, measured using the MTWS. β: Standardized coefficients. B:
Unstandardized coefficients. Adjusted R2: 0.087. CPD: Cigarettes equivalents per day. * Significant at α = 0.05.

Table 3.4 Loadings of the MTWS Items on the Identified Factor
Item of the MTWS
Item Loadings on The Identified
Factor
Restlessness
0.835
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Anger/Frustration/Irritability

0.825

Anxiety

0.787

Difficulty Concentrating

0.754

Insomnia

0.740

Depressed Mood

0.678

Increased Appetite

0.452

Craving

0.377

MTWS: Minnesota Tobacco Withdrawal Scale.

CHAPTER 4. NICOTINE WITHDRAWAL AND SUBSTANCE USE AMONG
TOBACCO-USING PATIENTS WITH MENTAL ILLNESS
4.1 Introduction
Despite the major strides accomplished in reducing adult tobacco use over the
past few decades, people with mental illness (MI) remain disproportionately affected by
tobacco use prevalence when compared to the general population.1,82,109,110 In fact, people
with MI are twice as likely to use tobacco compared to the general population, ostensibly
consuming roughly 44% of all cigarettes produced annually in the United States.6,7
Because of this staggering inclination toward tobacco use, people with MI have a higher
risk for heart, cerebrovascular disease, and chronic respiratory diseases and cancers.111
Actually, people with MI account for more than one-third of the U.S. annual deaths
attributed to tobacco use.1,8 Hence, efforts to promote tobacco treatment with this
population are critically important.
Tobacco dependence treatment efforts among people with MI are associated with
lowering the likelihood of being discharged against medical advice in the psychiatric
hospital setting, enhancing quality of life, and several other positive physical and
psychological health outcomes.10,11,111 Importantly, tobacco users with MI report
motivation levels to quit tobacco comparable to those of the general population.1,112 To
support patients’ increased motivation to stop tobacco use, psychiatric institutions in the
United States have increasingly endorsed tobacco-free policies and enhanced tobacco
treatment services during inpatient hospitalizations.3,51,113,114 These tobacco-free policies
have been shown to have positive tobacco cessation outcomes.3,51,113,114
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Nicotine withdrawal (NW) is an important barrier that impedes tobacco
dependence treatment and is often an unintended consequence of tobacco-free policies in
acute hospitalizations. NW is a set of symptoms that occur after abstaining from or
reducing the amount of tobacco normally consumed.12 NW syndrome is characterized by
the presence of four or more of the following symptoms within a 24 hour period of
tobacco abstinence: anxiety; irritability, frustration, or anger; increased appetite;
difficulty concentrating; depressed mood; restlessness; and insomnia.12 NW is an under
studied issue, and it is associated with the likelihood of unsuccessful quit attempts in the
tobacco-using MI population.11,19 As compared to those without, tobacco users with
substance use disorders (SUD; e.g. cannabis, cocaine, and alcohol) tend to experience
greater NW.19 Moreover, there are high rates of lifetime co-occurring SUDs observed in
tobacco-using patients with MI (11% to 52%).29-31 Yet in consideration of the high
prevalence of tobacco use among those with co-occurring substance use disorders and
MI, the relationship between SUD and NW in this population is poorly studied. Thus, in
order to guide treatment in tobacco-free psychiatric institutions, it is crucial to understand
the experience of NW among tobacco users with concurrent MI and SUDs during
hospitalization.
NW is experienced by up to 65% of tobacco users with MI.18 In fact, MI is
associated with at least 44% of all NW diagnoses in the general population.19 Among
those at greatest risk for NW are tobacco users with psychotic disorders and mood or
anxiety disorders, compared to other MI diagnoses.19 NW has been linked to a number of
factors among tobacco users with MI, such as sex, level of nicotine dependence, severity
of psychiatric symptoms, alcohol and drug use, and anxiety and depression levels.18,21,58,62
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If left untreated, NW can hinder the provided psychiatric care and lower the success rate
in quitting tobacco use through relapse.11,19
Given the scarcity of studies examining NW among people with concurrent
substance use and MI, the purpose of this study was to examine the nature of the
relationships between psychiatric diagnoses, substance use, and NW severity among
psychiatric inpatients. Specifically, among inpatients in a tobacco-free psychiatric
facility, this study aimed to evaluate whether co-occurring substance use moderates the
relationship between psychiatric diagnosis and NW severity. The psychiatric diagnoses
considered in this analysis includes psychotic disorders (yes/no) and mood or anxiety
disorders (yes/no). The hypotheses were:
i.

Among tobacco-using patients diagnosed with psychotic disorders (e.g.,
schizophrenia, schizoaffective, or psychotic disorder not otherwise specified), the
concurrent use of each of the following substance classes: alcohol; cannabis;
hallucinogens; inhalants; stimulants; opiates, pain killers, or heroin; sedatives,
hypnotics, or anxiolytics; or poly-substances, within the past 12 months prior to
admission, would serve as a moderator to NW severity (See Figure 4.1, A).

ii.

Among tobacco-using patients diagnosed with mood or anxiety disorders (e.g., major
depressive disorder, bipolar disorder, or post-traumatic stress disorder), the
concurrent use of each of the following substance classes: alcohol; cannabis;
hallucinogens; inhalants; stimulants; opiates, pain killers, or heroin; sedatives,
hypnotics, or anxiolytics; or poly-substances, within the past 12 months prior to
admission, would serve as a moderator to NW severity (See Figure 4.1, B).
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4.2 Methods
4.2.1 Design
This observational, retrospective study used longitudinal data to perform a
secondary data analysis of patients’ chart records from a regional psychiatric hospital in
Kentucky. The original research, from which these data were obtained, examined NW
symptoms and motivation to quit smoking after offering nicotine replacement therapy
(NRT) at admission for newly admitted psychiatric inpatients.57
4.2.2 Sample and setting
Data for this analysis were derived from psychiatric hospital admission charts
between January 1 and December 31, 2016. The psychiatric hospital is a tobacco-free,
239-bed state-owned institution in Kentucky, which provides tobacco treatment services
consistent with evidence-based practices.96,115 These services include assessing patients’
tobacco use characteristics and readiness to quit, NW symptoms; and providing practical
cessation counseling and U.S. Food and Drug Administration (FDA)-approved smoking
cessation medication (i.e., NRT), as needed, during hospitalization. This tobacco
treatment service is provided by a nurse certified in tobacco treatment. Data from all
tobacco-using patients who had been assessed for NW by the tobacco treatment nurse,
after at least 24 hours of admission, were included in the analyses. Data from patients
who were unable to respond to the tobacco treatment nurse due to impaired cognitive
ability (often related to the psychiatric illness for which they were admitted) or who
refused to respond were excluded from the analyses.
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4.2.3 Measures
4.2.3.1 Demographics and mental illness diagnosis
Information retrieved from medical records included age (in years), sex, ethnicity
(White vs. non-White), and educational status (less than high school/special education vs.
GED vs. Associate or higher degree). In addition, each patient’s primary discharge
diagnosis for this admission, hospitalization period (in days), time till assessment for NW
(in days) after admission, and the number of lifetime prior hospitalizations to that facility
were obtained. Patients’ primary discharge diagnoses, which were based on the ICD-10
criteria,116 were categorized into psychotic (e.g., schizophrenia, schizoaffective disorder,
psychosis not otherwise specified) vs. mood or anxiety (e.g., major depressive disorder,
bipolar disorder, generalized anxiety disorder, mood disorder not otherwise specified) vs.
substance use (e.g., substance-induced mood or psychotic disorder, alcohol use, cocaine
use, opiate use, etc.) vs. other (i.e., personality/malingering, cognitive/traumatic brain
injury, adjustment disorders, or altered mental status not otherwise specified) disorders.
We adopted this categorization of psychiatric disorders because patients with mood or
anxiety disorders were found to be best conceived as subfactors for a higher-order factor
(i.e., internalizing disorders), and patients with psychotic and substance use disorders
have been categorized separately in the literature.19,101,117
4.2.3.2 Tobacco use characteristics
Data on type of tobacco use (cigarettes vs. non-cigarettes) and timing of receiving
NRT during hospitalization (i.e., not given vs. at admission vs. on the unit) were retrieved
from patients’ charts. Due to the poly-tobacco products used by patients (i.e., cigarettes,
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chew tobacco, electronic cigarettes, cigars, and pipes), cigarette-equivalents per day
(CePDs) were calculated; i.e., four cigarettes were deemed equivalent for every cigar, 20
cigarettes was conservatively imputed for one electronic cigarette used per day, and 2.5
packs of cigarettes were equivalent to one can/tin of moist tobacco per day.81,100
4.2.3.3 Substance use classes
Self-reported substances used by patients in the 12 months prior to admission
were categorized into the following classes: alcohol; cannabis – including synthetic
cannabinoids (also known as spice);118 hallucinogens – including lysergic acid
diethylamide (LSD), phencyclidine (PCP), ecstasy, and psilocybin mushroom; inhalants –
including gasoline, glue, paint, and butane; stimulants – including cocaine,
methamphetamines, Adderall, and synthetic cathinones (also known as bath salts);119
sedatives, hypnotics, or anxiolytics – including barbiturates, antihistamines, and
benzodiazepines; and opiates – conventionally including pain killers and heroin. This
categorization of drugs classes was adopted from the DSM-V classification of substancerelated and addictive disorders.12 In addition, patients were grouped in terms of any
substance use and poly-substance use (defined as the use of more than one drug
regardless of class) over the past year prior to admission.
4.2.3.4 NW and NW syndrome
The Minnesota Tobacco Withdrawal Scale (MTWS) is a self-report questionnaire
consisting of 8 items, based on the Diagnostic and Statistical Manual of Mental
Disorder, Fourth Edition, Text Revision, (DSM-IV-TR) criteria for the diagnosis of NW
(i.e., dysmorphic/depressed mood, insomnia, irritability/frustration/anger, anxiety,
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difficulty concentrating, restlessness, increased appetite/weight gain), in addition to
craving – excluding the sign of decreased heart rate.13,83 Each of the eight items
represents a specific symptom of the NW syndrome, scored from 0 (no symptoms) to 4
(severe symptoms), with a summative total score ranging between 0 and 32. The MTWS
has demonstrated adequate internal consistency (alpha=0.77) in previous studies.92,93 Of
note, the DSM-IV-TR indicates that four or more of the aforementioned symptoms are
required for a NW syndrome diagnosis.13
4.2.4 Data analysis
During the time-frame of this evaluation, chart data indicated that 1,702 patients
were tobacco users. Of the total number of patients admitted during this time (N = 2751),
115 (4.2%) refused to be assessed for NW; and 1,231 (44.7%) were not assessed because
of the severity of their psychiatric symptoms, were not available for assessment when the
tobacco treatment nurse attempted to visit them, or stayed in the hospital for fewer than 3
days. Moreover, 101 of those assessed were repeated visits in the same year and were
excluded from the analysis to prevent potential confounding from prior assessments.
Hence, the study sample consisted of 255 tobacco-using patient records with single
admissions in the past 12 months, for whom the MTWS was completed.
Nominal and ordinal level variables were described using frequencies and
percentages, while means (M) and standard deviations (SD) were used to describe ratio
and interval level variables. Differences in sample demographics, history and treatment
of substance use, type of tobacco product consumed, length of hospital stay, time until
NW assessment, timing of receiving NRT, cigarette-equivalents per day (referred to in
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this paper as CePDs), number of prior hospitalizations, and the MTWS scores were
examined by MI diagnosis categories using Chi-square for nominal and ordinal level
variables, and Analysis of Variance (ANOVA) with Levene’s test of homogeneity of
variances (or Kruskal-Wallis test as appropriate) for interval and ratio level variables. In
addition, differences in proportions of use for each of the substance use classes across MI
diagnoses were examined using Chi-square.
The PROCESS macro for SPSS120 was used to assess the moderation effect for
each substance use class (categorical moderators: having used each substance use class
within the 12 month prior to admission vs. not) separately with each of the independent
variables (‘psychotic disorder’ compared to all other patients; and ‘mood or anxiety
disorder’ compared to all other patients). Moreover, throughout the moderation analyses,
race, sex, CePD, and the timing of NRT administration were included as covariates due
to their association with NW among patients with MI. Explicitly, among tobacco-using
patients hospitalized with MI, those who are African American and female experience
greater NW severity compared to their Caucasian and male counterparts.18 In addition,
the timing of NRT administration during hospitalization (not given vs. upon admission
vs. on the unit) has been associated with varying experiences of NW in this population.57
Finally, the amount of nicotine consumed per day can affect the NW experience.103,104
The alpha level was .05 for all inferential testing and the IBM SPSS statistical package
software (v. 24) was used for all calculations.
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4.3 Results
4.3.1 Sample characteristics
The study sample (N = 255) primarily consisted of White adults (89%) who had at
least a GED degree or higher level of education (72%) and were cigarette smokers (89%)
with a mean score of 3.2 (SD = 4.2) on the MTWS. Ninety-eight patients (38.4%) had
psychotic disorders and 81 patients (31.7%) had mood or anxiety disorders. Participants
reported a relatively high CePD (M = 23.7, SD = 16.7), and a most received NRT during
their hospitalization (82%). In addition, almost half the sample used cannabis (49%) and
roughly one third used either alcohol, stimulants, opiates, or sedatives. More than half
were poly-substance users, with more than two-thirds reporting the use of any type of
substances. Notably, only 29% of patients reported receiving substance use treatment in
the past. Based on the MI diagnosis categories, patients had significant differences in the
level of their education, χ2 (6, N = 255) = 13, p = .043, hospitalization duration in days,
χ2 (3, N = 255) = 45.8, p < .001, number of prior hospitalizations, χ2 (3, N = 255) = 16.8,
p = .001, time til NW was assessed after admission, χ2 (3, N = 255) = 11.8, p = .008,
having received substance use treatment in the past, χ2 (3, N = 248) = 14, p = .003, and
their MTWS scores, F (3, 251) = 1.8, p = .015. In terms of substance use per class,
significant differences across MI diagnoses were found in terms of hallucinogens use,
Likelihood Ratio test statistic χ2 (3, N = 203) = 15, p = .003, stimulants use χ2 (3, N =
203) = 23, p <.001, opiates use χ2 (3, N = 204) = 36, p < .001, sedatives use χ2 (3, N =
203) = 15, p = .002, poly-substance use χ2 (3, N = 202) = 21, p < .001, and any substances
use, χ2 (3, N = 202) = 16, p = .001. No other significant differences in demographics or
clinical variables were observed (see Table 4.1).
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4.3.2 Psychotic disorders and NW
Significant interaction effects on NW severity were found between having a
psychotic disorder and the concurrent use of the following substance classes:
hallucinogens (p = .002), inhalants, (p = .036), opiates, (p = .05), sedatives, hypnotics,
and anxiolytics (p < .001), stimulants (p = .012), and poly-substance use (p = .024) (see
Table 4.2). Specifically, among patients with psychotic disorders compared to patients
without, simple slopes analyses revealed significant negative relationships with NW
severity when the use of each of the following substances was reported: hallucinogens, b
= -1.09, 95% CI [-1.73, -.44], t = -3.32, p = .001; inhalants, b = -1.10, 95% CI [-1.97, .23], t = -2.50, p = .013; opiates, b = -.62, 95% CI [-1.16, -.09], t = -2.29, p = .023;
sedatives, hypnotics, and anxiolytics, b = -1.13, 95% CI [-1.56, -.70], t = -5.14, p < .001;
stimulants, b = -.71, 95% CI [-1.22, -.20], t = -2.77, p = .006; and poly-substance use, b =
-.43, 95% CI [-.80, -.06], t = -2.30, p = .022 (see Table 4.3 and Figure 4.2). This indicates
that the use of any of these substances was associated with lower severity in NW
symptoms. No significant moderation effect on NW was found between having a
psychotic disorders and alcohol or cannabis use.
4.3.3 Mood or anxiety disorders and NW
Significant interaction effects on NW severity were found between having a mood
or anxiety disorder and the concurrent use of hallucinogens (p = .021), and sedatives,
hypnotics, and anxiolytics (p = .022) (see Table 4.4). Specifically, among patients with
mood or anxiety disorders, compared to patients without, simple slopes analyses revealed
a significant positive relationship on NW severity when hallucinogens, b = .83, 95% CI
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[.23, 1.43], t = 2.74, p = .007, and sedatives, hypnotics, and anxiolytics use, b = .61, 95%
CI [.11, 1.11], t = 2.40, p = .017, were reported (see Table 4.5 and Figure 4.3). This
indicates that the use of any of these substances was associated with greater severity in
NW symptoms. No significant moderation effect on NW was found between having a
mood or anxiety disorders and alcohol, cannabis, inhalants, stimulants, opiates, or polysubstance use.
4.4 Discussion
The purpose of this study was to examine the nature of the relationship between
the co-occurring use of different classes of substances on NW severity among inpatient
tobacco users with psychotic or mood or anxiety disorders diagnoses. Among patients
with psychotic disorders, as compared to patients without, there was significantly lower
NW severity among those who reported past 12-month use of hallucinogens; inhalants;
opiates; sedatives, hypnotics, and anxiolytics; stimulants; or poly-substance use. On the
other hand, patients with mood or anxiety disorders, compared to patients without,
reported significantly higher NW severity when they reported past 12-month use of
hallucinogens or sedatives, hypnotics, and anxiolytics.
Previous research has reported differences in the NW experience among people
with and without MI. Smith, Homish, Giovino, and Kozlowski (2014)19 conducted a
secondary analysis of data on a nationally-representative sample of more than 43,000
civilian, non-institutionalized adults in the U.S., which were collected using face-to-face
computer-assisted interviews. Researchers found that people with both psychotic
disorders and mood or anxiety disorders were more likely to experience higher NW
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symptoms severity compared to the general public. These findings, however, do not
necessarily contradict ours (i.e., patients with psychotic disorders, may experience lower
NW severities, considering substance use profiles) in light of differences in samples’
characteristics. For instance, Smith et al. (2014)19 designated community-dwelling people
without MI as a comparison group of reference for NW severity, compared to
hospitalized patients with other MI diagnoses in our sample. In addition, substance use
profiles across MI groups in Smith et al. (2014)’s19 study were not accounted for in their
analyses. Nonetheless, it is worth mentioning that researchers found that patients with
past year alcohol use and drug use disorders had the lowest relative risk of having more
severe NW, in comparison to patients with psychotic and mood or anxiety disorders.19
We found that patients with mood or anxiety disorders may demonstrate higher
NW severities when hallucinogens or sedatives, hypnotics, and anxiolytics use was
reported. Similarly, in a sample of 8,213 community-dwelling current smokers,
Weinberger, Desai, and McKee (2010)55 found that participants with mood, anxiety,
alcohol, or substance use disorders were more likely to have greater NW symptoms, with
an increased likelihood for withdrawal-related discomfort and relapse, compared to
people without these conditions. However, researchers also found no interaction effect on
NW severity between having current mood or anxiety diagnoses and the co-morbidity of
alcohol or substance use disorder.55 Again, the resulting discrepancy in the interaction
effect between substance use and MI on NW severity between ours and Weinberger et al.
(2010)’s55 study can be attributed to using different reference groups for comparison,
with dissimilar MI conditions. Explicitly, psychiatric hospitalization for patients with MI
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is indicative of greater influence of MI on functioning and general wellbeing of the
individual, compared to community-dwelling people with MI.
In addition, different interaction outcomes between substance use and MI on NW
can also be attributed to varying substance use profiles of the comparison groups used as
reference (i.e., community-dwelling people with substance use problems vs. patients with
MI and co-morbid substance use). For instance, while the lifetime prevalence rates of
substance use among patients with a diagnosed MI and the general public are both
considerably high, 36-58% and up to 83%, respectively,29,31,121,122 only 12-20% of people
in the community with MI and substance dependence used mental health services,
compared to up to 50% among patients with severe MI and substance dependence.123,124
Significant differences in the utilization of mental health services have also been
recognized across patients with MI diagnosis, based on their substance use profiles.
Specifically, among patients with psychotic, mood, or anxiety disorders who required
psychiatric hospitalization during the course of their MI, an overall significantly higher
annual contact with outpatient clinics, emergency departments, and days of
hospitalization were observed among those with concurrent substance use disorders.32
Moreover, a higher percentage of patients with MI and co-morbid substance use disorders
were found utilizing specialty tertiary inpatient mental health programs, in comparison to
utilizing specialty outpatient and community mental health services.125 This inconsistency
in utilizing mental health services among people with and without MI, who also have
substance use problems, can be perceived as an indicator of the severity of the underlying
substance use problem in patients with MI. Such underlying severity may potentially
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explain NW experience during psychiatric hospital stays compared to NW experienced
among people with MI and substance use problems in the community setting.
In a study examining NW severity correlates among patients with MI during
psychiatric hospitalization, who also received NRT during their hospital stay (70%),
Soyster, Anzai, and Prochaska (2016)18 found that NW severity was positively associated
with alcohol and drugs use. However, around only 25% of their sample had psychotic
disorders, while patients with mood disorders constituted 60% of their sample. While
Soyster et al. (2016)18 did not assess NW severity by MI diagnoses or specified substance
use classes in their sample, their results are comparable to our finding of higher NW
among patients with mood or anxiety disorders.18
Positive symptoms found in patients with psychotic disorders have been linked to
hyperactivity in the dopaminergic cerebral mesolimbic neural pathway.126,127 Nicotine
exposure is also believed to increase the firing of dopamine neurons in the mesolimbic
tract.128 On the other hand, NW is associated with decreased levels of dopamine in the
nucleus accumbens (i.e., mesolimbic tract).128-130 One possible interpretation of the lower
severities in NW observed among patients with psychotic disorders in our study is the
associated, either direct or indirect, increased activity in different dopaminergic neuronal
pathways coupled with hallucinogens; inhalants; opiates; sedatives, hypnotics, and
anxiolytics; stimulants; or poly-substances use.131-137 Moreover, non-adherence to
antipsychotic medications is common in this patient group, especially when accompanied
with substance use.138,139 This non-adherence to antipsychotics is associated with rebound
activation of the dopaminergic response, leading to increased effects of dopamine,140 and
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potentially to fewer NW symptoms. But these findings are speculative at best and require
further investigation.
Patients with mood or anxiety disorders are characterized by having decreased
levels of serotonin, among others, from the brain stem.141,142 Nicotine exposure has been
linked to elevated levels of serotonin among both, smokers and nonsmokers.143
Alternatively, NW is believed to decrease serotonin release in the forebrain and limbic
system.130,144 A possible rationale of the higher NW severity found among mood or
anxiety disorder patients reporting sedative, hypnotic, and anxiolytic use in our sample is
that these drugs work on further decreasing serotonin levels in the brain.145,146
Hallucinogen use, on the other hand, is associated with increased levels of serotonin in
the brain.131,147 However, antipsychotic use, which is common among patients with mood
or anxiety disorders, is linked to reversing hallucinogen-induced increases in serotonin
levels,148 possibly leading to higher NW symptoms.
The interpretation of the results of the study reported here need to be considered
in light of a number of limitations. Approximately 35% and 62% of patients with
psychotic and mood or anxiety disorders, respectively, were poly-substance users.
Further, approximately 50% within each MI diagnoses category used either alcohol or
cannabis. Drug-drug overlap and effect on NW for each substance use category was not
analyzed in this study. Also, due to a lack of data from the parent study, the impact of
treatment of substance use withdrawal could not be assessed. Furthermore, duration and
frequency of substance use class data was not available in the dataset. Importantly,
treatment for and last dose of the used substance prior to hospitalization was also
unavailable. Moreover, the similarity of NW symptoms with signs and symptoms of MI
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and antipsychotic side effects may have affected the NW scores; thus, longitudinal
research on NW in this population is warranted, along with the effects of the sensitivity
of NW across different MI diagnoses. The generalizability of our results is affected by
the fact that our sample constituted only 24% of the total tobacco users admitted to the
psychiatric facility over one year. The remaining majority of eligible patients were either
unable to respond due to psychiatric symptoms severity, being hospitalized for a short
duration of time, or refusing to be assessed for NW. Finally, since multiple comparisons
were performed for each independent variable from the same dataset, there was a risk for
inflating type 1 error. When Bonferroni corrections were applied for each independent
variable tested, the new p – value was set at .00625 (i.e., .05 divided by the 8 substance
use classes for each independent variable). Accordingly, the only significant interaction
effects on NW severity were found among patients with psychotic disorders who used
hallucinogens or sedatives, hypnotics, or anxiolytics.
4.5 Conclusion
Notwithstanding the inherent limitations in this secondary data analysis, we found
that concurrent substance use among patients with psychotic and mood or anxiety
disorders resulted in varying NW experiences. Moreover, the findings provide insight on
the vulnerability to NW among patients with substance use admitted to psychiatric
institutions. Hence, an emphasis on early detection of NW after psychiatric admission,
particularly among tobacco-using patients with substance use disorders, is warranted.
Future research is needed to examine the longitudinal trajectory of NW symptoms during
hospitalization for different substance use classes across different MI diagnoses. Such
studies can provide important directions for tailoring tobacco dependence treatment
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among psychiatric inpatients to curb the disproportionate tobacco-related disease burden
and mortality in this population.
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Table 4.1 Differences in Sample Characteristics by Primary Psychiatric Diagnosis Categories at Discharge
Mean ± SD, Median [25th percentile, 75th percentile], or N (%)
Substance
use
disorders
(n = 40)

Other
disorders⁹

(n = 98)

Mood or
anxiety
disorders
(n = 81)

41 [31, 54]

46 [33, 54]

38 [31, 53]

36 [ 27, 49]

48 [28, 60]

142 (56)
113 (44)

60 (61)
38 (39)

39 (48)
42 (52)

22 (55)
18 (45)

21 (58)
15 (42)

Ethnicity
White
Non-White

228 (89)
27 (11)

82 (84)
16 (16)

76 (94)
5(6)

38 (95)
2 (5)

32 (89)
4 (11)

Education
Less than high school
GED
Associate or higher degree

70 (26)
82 (32)
103 (40)

26 (27)
26 (27)
46 (47)

15 (19)
30 (37)
36 (44)

14 (35)
16 (40)
10 (25)

15 (42)
10 (28)
11 (31)

Hospitalization period (in days) §

8 [5, 15]

13 [8, 24]

6 [4, 10]

6 [4, 7]

9 [5, 18]

<.001*

Number of prior hospitalizations§

1.4 ± 3.5

2.2 ± 4.4

1.2 ± 2.9

0.6 ± 2.9

0.5 ± 1.1

.001*

Tobacco use type
Cigarettes
Non-cigarettes

228 (89)
27 (11)

88 (89)
10 (10)

73 (90)
8 (10)

35 (88)
5 (13)

32 (89)
4 (11)

23.7 ± 16.7

22.5 ± 14.6

23.9 ± 19.5

26.6 ± 16.9

23.2 ± 14.7

.613

Time till NW assessment§

3 [2, 6]

4 [2, 9]

2 [1, 5]

3 [2, 5]

3 [2, 6]

.008*

Receiving NRT
Not given
At admission
On the unit

48 (19)
175 (69)
32 (13)

26 (27)
62 (63)
10 (10)

10 (12)
60 (74)
11 (14)

5 (13)
26 (65)
9 (23)

7 (19)
27 (75)
2 (6)

.069
.341
.123

86 (42.4)
99 (49)
22 (11)
6 (3)
60 (30)

27 (39)
33 (47)
3 (4)
2 (3)
9 (13)

31 (48)
33 (51)
8 (12)
3 (5)
20 (31)

14 (38)
21 (55)
10 (27)
1 (3)
21 (57)

14 (45)
12 (39)
1 (3)
0 (0)
10 (32)

.664
.558
.003*,
.493
<.001*

64 (31)

8 (11)

26 (39)

24 (65)

6 (19)

<.001*

55 (27)

12 (17)

22 (34)

17 (46)

4 (13)

.002*

107 (53)

24 (35)

40 (62)

29 (78)

14 (45)

153 (76)

44 (64)

52 (80)

36 (97)

21 (68)

73 (29)

26 (28)

23 (29)

20 (50)

4 (11)

3.2 ± 4.2

2.4 ± 3.6

3.9 ± 4.7

4.1 ± 4.8

3.0 ± 4.3

Variable

Age (in years)§

Total
sample

Psychotic
disorders

(N = 255)

p-Value

(n = 36)

Gender

.06
.363

Males
Females

Cigarettes equivalent per day (CePD)

Substance use class
Alcohol˥˥
Cannabis˥
Hallucinogens˥˥
Inhalants˥˥˥
Stimulants˥˥
Opiates – including pain killers
and
heroin˥
Sedatives, hypnotics, and
anxiolytics˥˥
Poly-substance Use ˥˥˥
Yes
Any substances use ˥˥˥
Yes
Substance use treatment‡
Yes
MTWS scores

.093

.043*

.974

<.001*
.001*
.003*

˥ 51

missing cases.
missing cases.
˥˥˥ 53 missing cases.

Pertinent to the Likelihood Ratio p – value.
˥˥ 52

82

.015*

‡ Seven missing cases.
* Significant at α = 0.05.
§
Analyzed using Kruskal-Wallis test.
NRT: Nicotine Replacement Therapy.
MTWS: Minnesota Tobacco Withdrawal Scale.
⁹ Includes personality/malingering, cognitive/traumatic brain injury, adjustment disorders, or altered mental status (not
otherwise specified) disorders.
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Table 4.2 Parameters of Significant Interaction Terms for Separate Regression Models Examining the Interaction of Psychotic
Disorder Status and Different Substance Use Classes on NW
Substance use class used
Interaction term
t – value
95% CI
p – value of
R2 of the model p – value of the
in the moderation
coefficient
interaction term
model
analysis model
Hallucinogens
-1.04
-3.01
-1.72, -.36
.002
.125
< .001
Inhalants
-.96
-2.11
-1.87, -.06
.036
.117
< .001
Opiates
-.57
-1.94
-1.18, .00
.05
.106
< .001
Sedatives, Hypnotics, and
-1.27
-4.99
-1.77, -.77
< .001
.178
< .001
Anxiolytics
Stimulants
-.74
-2.55
-1.30, -.17
.012
.121
< .001
Poly-substance use
-.55
-2.27
-1.03, -.07
.024
.124
< .001
Note: Dependent variable for all models was NW severity. Covariates included in all models: psychotics disorder diagnosis vs. not; substance use class
(yes vs. no); race (white vs. non-White); sex, CePD; timing of NRT administration; and interaction term of specific substance use class by psychotic
disorder diagnosis.
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Table 4.3 Substance Use Moderators of The Relationship Between Psychotic Disorder Status and NW
Substance Use Class
b
Standard Error
t
95% Confidence
(S.E.)
Interval (CI)
Hallucinogens Use
Reported
-1.09
.33
-3.32
-1.73, -0.44
Not Reported
-0.047
.12
-0.38
-0.29, 0.20
Inhalants Use
Reported
-1.10
.44
-2.50
-1.97, -0.23
Not Reported
-0.14
.12
-1.17
-0.37, 0.10
Opiates Use
Reported
-0.62
.27
-2.29
-1.16, -0.09
Not Reported
-0.04
.14
-0.28
-0.31, 0.23
Sedatives, Hypnotics, and anxiolytics
Reported
-1.13
.22
-5.14
-1.56, -0.70
Not Reported
0.14
.13
1.10
-0.11, 0.39
Stimulants Use
Reported
-0.71
.26
-2.77
-1.22, -0.20
Not Reported
0.02
.13
0.17
-0.24, 0.29
Poly-substance Use
Reported
-0.43
.19
-2.30
-0.80, -0.06
Not Reported
0.16
.15
0.75
-0.19, 0.42
Note: all analyses controlled for sex, race, CePD, and timing of NRT administration. * Significant at α equals 0.05.

p - Value

.001*
.707
.013*
.244
.023*
.784
< .001*
.275
.006*
.866
.022*
.454

Table 4.4 Parameters of Significant Interaction Terms for Separate Regression Models Examining the Interaction of Mood or
Anxiety Disorder Status and Different Substance Use Classes on NW
Substance use class used
Interaction term
t – value
95% CI
p – value of
R2 of the model p – value of the
in the moderation
coefficient
interaction term
model
analysis model
Hallucinogens
.77
2.32
.12, 1.42
.021
.128
< .001
Sedatives, Hypnotics, and
.66
2.30
.01, 1.23
.022
.125
< .001
Anxiolytics
Note: Dependent variable for all models was NW severity. Covariates included in all models: psychotics disorder diagnosis vs. not; substance use class
(yes vs. no); race (white vs. non-White); sex, CePD; timing of NRT administration; and interaction term of specific substance use class by Mood or
Anxiety disorder diagnosis.
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Table 4.5 Substance Use Moderators of the Relationship Between Mood or Anxiety Disorder Status and NW
Substance Use Class
b
Standard Error
t
95% Confidence
p - Value
(S.E.)
Interval (CI)
Hallucinogens Use
Reported
0.83
.30
2.74
0.23, 1.43
.007*
Not Reported
0.61
.13
0.46
-0.20, 0.31
.648
Sedatives, Hypnotics, and anxiolytics
Reported
0.61
.25
2.40
0.11, 1.11
.017*
Not Reported
-0.05
.13
-0.41
-0.32, 0.21
.684
Note: all analyses controlled for sex, race, CePD, and timing of NRT administration. * Significant at α equals 0.05.
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A.

Hypothesis 1

B.

Hypothesis 2

Figure 4.1 Moderation analyses models for hypotheses 1 and 2. Substance use classes include: alcohol; cannabis;
hallucinogens; inhalants; stimulants; opiates – including pain killers and heroin; sedatives, hypnotics, and
anxiolytics; and poly-substance use. note: a series of separate moderation models were rendered for each
substance use class.
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CHAPTER 5. SUMMARY
5.1 Background and Purpose
The primary goal of this dissertation is to enhance understanding of nicotine
withdrawal (NW) among tobacco users with mental illness (MI). A significant proportion
of tobacco users with MI experience NW,18 which is linked to lowering the likelihood of
their successful quit attempts;11,19 and further predisposing them to health and economic
adversities, and maintaining high mortality tobacco-related rates.1,8,9 Since NW is
experienced in greater intensity among people with MI,19 this unique feature of NW
relative to those with MI may also serve as a contributing factor for the staggering gap in
the proportion of tobacco use between those with- and without MI.37,38
Three manuscripts are introduced in this dissertation: 1) a systematic review of
the research literature published from 2008 to 2019, to synthesize and summarize factors
associated with NW among tobacco users with MI; 2) a psychometric properties
evaluation of the Minnesota Tobacco Withdrawal Scale (MTWS) in a sample of tobacco
users with MI; and 3) an observational, retrospective study of longitudinal data using
moderation analysis to examine the nature of the relationships between psychiatric
diagnoses and substances of abuse with NW severity among psychiatric inpatients.
Quitting tobacco use is associated with lowering the likelihood of being
discharged against medical advice among hospitalized psychiatric patients, reporting
better quality of life, and reducing anxiety, depression, and stress levels compared to
those who sustain tobacco use.9-11 Quitting tobacco use is hindered by relapse, which is
associated with NW.42-48 This chapter summarizes the findings from each manuscript in
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this dissertation and how these findings may help guide clinical practice, promote policy
development, and steer future research.
5.2 Summary of findings
Chapter 2 in this dissertation presented a systematic review of the literature.
Fifteen articles published from 2008 to 2019 studying NW among tobacco users with MI
as a primary or a secondary outcome measure were identified. The identified articles
employed experimental and non-experimental designs, and they summarized the
correlates of NW experienced by tobacco users with MI. These correlates include: MI
diagnoses of psychotic and mood or anxiety disorders, higher severity of psychiatric
symptoms, race (i.e., African Americans), sex (i.e., women), higher nicotine dependence,
previous or concurrent drug and alcohol use, low confidence in one’s ability to quit,
pharmacological interventions to treat tobacco use (i.e., varenicline), high pre-quit
anxiety and depression levels, and timing of offering and use of nicotine replacement
therapy (NRT) during a tobacco-free psychiatric hospitalization (i.e., upon admission vs.
later during hospitalization). These findings outline the importance of assessing the
correlates of NW among tobacco users with MI. For example, research shows that people
with psychotic disorders have higher odds of having NW compared to other psychiatric
diagnoses.19 This may suggest that tobacco treatment for tobacco users with psychotic
disorders may need diagnostic-tailored approaches for minimizing NW. Also, these
correlates discern a form of disparity in offering NRT during psychiatric hospitalization
against African Americans.18 The fact that African Americans are less likely to be offered
NRT is critically important as we change standards of practice for tobacco treatment in
psychiatric hospitals. Give what we know about NW and psychotic disorders, it would be
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especially important to ensure access to NRT for African Americans with psychotic
disorders to promote successful tobacco cessation outcomes.
Chapter 3 in this dissertation examined the psychometric properties of the MTWS
in a sample of 255 patients admitted to a tobacco-free, state psychiatric facility in
Kentucky. Reliability testing was conducted using the Cronbach’s alpha, item-total, and
inter-items correlation coefficients. Further, validity testing was examined using
hypothesis testing and exploratory factor analysis. We hypothesized that higher number
of cigarettes smoked per day were predictive of greater NW symptoms severity when
measured using the MTWS. The reliability analysis yielded a Cronbach’s alpha
coefficient of 0.763, inter-item correlation coefficient of 0.393, and item-total
correlations between 0.291 and 0.691. The overall Cronbach’s alpha of the instrument did
not decline below 0.698 when any of its items were deleted. A multivariate general linear
regression was used to test the validity of the MTWS. The regression model showed that
the number of cigarettes smoked per day increased NW symptoms severity, when
measured using the MTWS, by 0.147 for each reported cigarette smoked per day,
confirming the validity of using the MTWS in this population. Also, an exploratory factor
analysis identified one factor with an eigenvalue of 3.920, which explained 49% of the
total variance in the MTWS scores. Most of the MTWS’s items loaded significantly on
this factor with item loadings ranging between 0.452 and 0.835. Briefly, this manuscript
concluded that the MTWS demonstrated reliable and valid psychometric properties for
measuring NW among tobacco users with MI during a psychiatric tobacco-free
hospitalization. This instrument is recommended for use in clinical psychiatric practice to
identify NW in tobacco-using patients.
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Chapter 4 examined whether co-occurring use of substances of certain classes
moderate the relationship between psychiatric diagnosis and NW severity. The
psychiatric diagnoses considered in this manuscript included psychotic disorders (yes/no)
and mood or anxiety disorders (yes/no). The substance use classes that each served as a
moderator included: alcohol; cannabis; hallucinogens; inhalants; stimulants; opiates, pain
killers, or heroin; sedatives, hypnotics, or anxiolytics; or poly-substances. Throughout the
moderation analyses, race, sex, cigarette-equivalents smoked per day, and the timing of
NRT administration were included as covariates due to their association with NW among
tobacco users with MI.18,57,103,104
Among study participants with psychotic disorders, as compared to those without,
our moderation analyses revealed significantly lower NW severity among those who
reported the past 12-month use of hallucinogens; inhalants; opiates; sedatives, hypnotics,
and anxiolytics; stimulants; or poly-substance use. On the other hand, participants with
mood or anxiety disorders diagnoses, compared to those without, reported significantly
higher NW severity when reporting the past 12-month use of hallucinogens or sedatives,
hypnotics, and anxiolytics. This manuscript indicated that, in addition to differences in
NW among varying MI diagnoses,19 NW experiences can vary within patients with the
same MI diagnosis by different histories of substances used.
5.3 Contribution of dissertation
This dissertation contributes to research and practice in a number of ways. First,
the findings identify a number of factors correlating to NW among tobacco users with
MI. These findings can help clinicians identify tobacco users with MI who are at greater
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risk for developing NW. Once these high-risk patients are identified, clinicians can plan
and evaluate intervention strategies to minimize NW and promote tobacco abstinence.
For example, a heavy smoker African American woman newly admitted to a tobacco-free
psychiatric facility with a diagnosis schizophrenia is expected to experience high levels
of NW. Second, this dissertation adds to the research literature that supports the use of
the MTWS with tobacco users to assess NW during psychiatric tobacco-free
hospitalization. This gives clinicians and researchers a reliable and valid assessment tool
to guide actions that could alleviate or reverse these symptoms, leading to more
successful cessation and lower chance of relapse. Last, this dissertation discovered
significant differences in NW in tobacco users with the same MI diagnoses (i.e.,
psychotic and mood or anxiety disorders), based on the use of certain classes of
substances. This finding provides support for tailoring tobacco treatment and relapse
prevention based on particular patients with certain MI diagnoses, and also taking into
consideration use of certain substances. For example, a tobacco-using patient with major
depression disorder, who also abuses anxiolytics, may experience higher NW compared
to another patient with major depressive disorder who does not.
5.4 Limitations
This dissertation has a number of limitations. The systematic review included
experimental and non-experimental studies, with varying research designs, from various
settings and with distinct participants’ diagnoses and characteristics. This may have
affected the generalizability of our conclusions. However, it is a strength that studies used
different designs and methods with different populations and in different settings,
providing a more robust understanding of the factors that impact NW in this high-risk
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population. Chapters 3 and 4 involved secondary data analysis from a parent study which
adopted a cross-sectional research design using a convenience sample.57 That sample
represented around one-quarter of the total number of tobacco-using patients admitted to
a psychiatric hospital over a 1-year period.57 Also, the majority of that sample received
NRT during hospitalization, which may have resulted in lower than average NW scores
during hospitalization. Thus, the studies using this data set may have been subject to
selection bias, threatening internal validity. With regard to Chapter 4, an important
limitation was repeated analyses from the same dataset and the fact that around one- to
two-thirds of participants reported using more than one substance use class (i.e., overlap
of use across classes), with around 50% of participants within each MI category using
either alcohol or cannabis. This may have limited the isolated effect of a specific
substance use class on NW.
5.5 Recommendations for future research
We recommend that nurses and researchers offer and evaluate the impacts of
offering NRT as part of evidence-based tobacco treatment services during psychiatric
hospitalization to reduce disparities in tobacco use. Research is needed to study whether
reducing depression and anxiety levels before embarking on a quit attempt would lead to
different tobacco abstinence outcomes among the MI population. Future research needs
to examine the efficacy of different instruments in measuring NW over an extended
period of psychiatric hospitalization. Finally, research to understand the longitudinal
trajectory of NW symptoms during hospitalization for patients who use different classes
of substances with different MI diagnoses is needed.
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